

# SWISS BIOTECH DAY 2024

© Swiss Biotech Association

April 22-23, 2024  
Congress Center Basel

Host:



# Conference program at a glance

## Monday, April 22, 2024

10:00-11:00	<b>Swiss Biotech Association general assembly</b> (by invitation only)	Room Sydney
11:00	Registration opens	Entrance
11:00-11:45	<b>Press conference</b> (media only)	Room Rio
11:00-18:45	Exhibition throughout the day	Foyer 2 <sup>nd</sup> floor and Hall 4.1 p. 48
	Poster presentations throughout the day	Hall 4.1 p. 56
	Global Village and Roundtable discussions	Room San Francisco p. 19
	Partnering throughout the day	Room San Francisco and Hall 4.1 p. 5
11:30-13:00	Lunch	Foyer 2 <sup>nd</sup> floor and Hall 4.1
12:30-14:00	<b>Plenary session I</b>	Room Montreal p. 7
14:00-15:00	Coffee break	
14:10-18:30	<b>Parallel tracks</b>	
14:30-16:45	<b>PUREOS</b> Emerging biotech company presentations	Room Singapore p. 8
14:10-17:15	<b>IP</b> Clinical stage biotech company presentations	Room Samarkand p. 10
14:30-18:00	<b>LONZA</b> Advanced biotech company presentations	Room Osaka p. 11
16:45-17:30	Start-up pitch Nucleate	p. 9
17:45-18:30	Venture Leader pitch	p. 9
18:00-18:45	International reception of the Global Village	Room San Francisco p. 19
18:45-21:00	Evening reception	Foyer 2 <sup>nd</sup> floor and Hall 4.1 



**Free WiFi**  
SSID: Free Messe Basel  
Free SMS-Login  
(one Login for each device)






**X**  
#swissbiotechday



**LinkedIn**  
#swissbiotechday

14:30-18:30 <b>Panel discussions</b>	14:30-18:30 <b>Panel discussions</b>	14:30-18:30 <b>Panel discussions</b>	16:30-17:15 <b>Panel discussions</b>
Room Sydney p. 12	Room Rio p. 14	Marriott Hotel p. 16	Room Montreal p. 18
14:30-15:15 <b>Panel 1</b>	14:30-15:15 <b>Panel 5</b>	14:30-15:15 <b>Panel 9</b>	
p. 12	p. 14	p. 16	
15:30-16:15 <b>Panel 2</b>	15:30-16:15 <b>Panel 6</b>	15:30-16:15 <b>Panel 10</b>	
p.12	p. 14	p. 16	
16:30-17:15 <b>Panel 3</b>	16:30-17:15 <b>Panel 7</b>	16:30-17:15 <b>Panel 11</b>	16:30-17:15 <b>Panel 13</b>
p. 13	p. 15	p. 17	p. 18
17:30-18:15 <b>Panel 4</b>	17:30-18:15 <b>Panel 8</b>	17:30-18:15 <b>Panel 12</b>	
p. 13	p. 15	p. 17	

## Tuesday, April 23, 2024

07:15	Registration opens	Entrance
07:30-17:00	Partnering throughout the day	Room San Francisco and Hall 4.1 p. 5
09:00-17:00	Exhibition throughout the day	Foyer 2 <sup>nd</sup> floor and Hall 4.1 p. 48
	Poster presentations throughout the day	Hall 4.1 p. 56
	Global Village and Roundtable discussions	Room San Francisco p. 19
09:00-09:45	<b>Pitching sessions</b>	
	<b>Next generation organ-on-chip &amp; organoids</b> Room Singapore p. 26	<b>Recent developments and future avenues in cell &amp; gene therapies</b> Room Sydney p. 26
10:00-12:00	<b>Plenary session II</b>	Room Montreal p. 28
12:00-13:30	Lunch	Foyer 2 <sup>nd</sup> floor and Hall 4.1 
12:00-16:45	<b>Parallel tracks</b>	
13:00-15:00	 <b>Emerging biotech company presentations</b> Room Singapore p. 29	 <b>Clinical stage biotech company presentations</b> Room Sydney p. 30
		<b>12:00-12:45 Panel 14</b> Room Osaka p. 32
		<b>13:00-16:45 LONZA</b> <b>Advanced biotech company presentations</b> p. 31
14:30-15:30	Coffee break	
16:00-17:00	Market place of the Global Village	Room San Francisco p. 19
17:00-18:30	Evening reception Foyer 2 <sup>nd</sup> floor	

### The pre-scheduled one-to-one meetings take place as follows:

Please check your individual meeting schedule for times and locations of your confirmed meetings. Need help? Please see the partnering help desk in Hall 4.1. <https://www.hellopartnering.com/login/index/SBD24>

supported by 



<b>Innovative companies in healthspan and longevity</b> Room Rio p. 27	<b>Investors pitch to the audience</b> Marriott Hotel p. 27
---	--

<b>12:15-16:45 Panel Discussions</b> Room Samarkand p. 33	<b>12:15-16:45 Panel Discussions</b> Room Rio p. 36	<b>12:15-16:45 Panel Discussions</b> Marriott Hotel p. 39	<b>13:00-14:00 Pitch Global Village</b> Room Montreal p. 42
<b>12:15-13:45 Pitch and panel 15 industrial biotech</b> p.33	<b>12:15-13:45 Pitch and panel 19 lab automation</b> p. 36	<b>12:15-13:45 Pitch and panel 23 health tech</b> p. 39	<b>13:00-14:00 International pitching session</b> p. 42
<b>14:00-14:45 Panel 16</b> p. 34	<b>14:00-14:45 Panel 20</b> p. 37	<b>14:00-14:45 Panel 24</b> p. 40	
<b>15:00-15:45 Panel 17</b> p. 34	<b>15:00-15:45 Panel 21</b> p. 37	<b>15:00-15:45 Panel 25</b> p. 40	
<b>16:00-16:45 Panel 18</b> p. 35	<b>16:00-16:45 Panel 22</b> p. 38	<b>16:00-16:45 Panel 26</b> p. 41	

# Welcome reception

Kindly supported by   

Welcome reception

Markthalle Basel

**We are excited to announce the very first welcome reception of the Swiss Biotech Day on Sunday, April 21, 2024.**

The Swiss Biotech Day will once again provide a platform in Basel for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing.

This inaugural gathering provides a prime networking opportunity, allowing attendees to connect and engage with peers before the event officially starts. Join us from 17:30 to 21:00 for an aperitif and an informal fun networking evening in anticipation of the lively days ahead.



# Plenary session I

Plenary session I

Room Montreal

Moderation: **Monika Jones**

**12:30 - Welcome local host**

**14:00** **Kaspar Sutter**, Head of the Department of Economic, Social and Environmental Affairs, Canton of Basel-Stadt

**Welcome organizer**

**Michael Altorfer**, CEO, Swiss Biotech Association

**European Biosolutions Coalition**

**Sofie Carsten Nielsen**, Director, European Biosolutions Coalition

**Marit Hvithamar Rystrom**, Leading Senior Advisor, European Biosolutions Coalition

**Panel on Longevity**

**Patrick Aebischer**, President emeritus, EPFL

**Greg Behar**, CEO, Recipharm

**Elisabeth Roider**, Partner and Chief Scientific & Medical officer, Maximon AG

**Alejandro Ocampo**, Assistant Professor, Université de Lausanne

**Amalio Telenti**, Executive Vice President, Vir Biotechnology









**Life Science Cares**

**Patrick Amstutz**, President, Swiss Biotech Association

**Div Gupta**, Partner, Cooley

# Emerging biotech companies

Presented by 

Time	Company	Room Singapore
14:30	Pureos Bioventures	
14:45	Engimmune Therapeutics	
15:00	Antion Biosciences	
15:15	Ymmunobio	
15:30	Haya Therapeutics	
15:45	Orio Therapeutics	
16:00	SEITO Biologics	
16:15	NewBiologix	

Moderation: **Dominik Escher & Anne Grahl**, Pureos Bioventures

See all information on the presenting companies here →

# Pitching sessions

Presented by 

## 16:45-17:30 Start-up pitch Nucleate

Room Singapore

### BioPitch: Igniting innovation at Swiss Biotech Day with Nucleate

Discover groundbreaking innovations from Switzerland's early-stage life science start-ups at Nucleate's pitching session. These start-ups, part of Nucleate's Activator program, are revolutionizing human health challenges. Run by academic trainees, Nucleate fosters technology commercialization, offering equity-free support and connecting budding entrepreneurs with a prestigious advisor network.

Moderation: **Rishika Agarwal**, Co Managing Director, Nucleate Switzerland | **Sara Svanberg**, Co Managing Director, Nucleate Switzerland

Jury: **Katharina Kreymborg**, SVP, CSO Partner Team, Curie.Bio | **Zoë Johnson**, CSO & CDO, M:M Bio | **Antoine Boulanger**, Principal, Forbion

16:45 Introduction

16:50 SYDRA

17:05 Inkocell

16:55 IMPLANZ

17:10 EVIIVE

17:00 inSEIT

17:15 DropGen

17:20 Voting and closing address

Presented by 

## 17:45-18:30 Venture Leaders pitch

Room Singapore

### Discover the Venture Leaders biotech opportunities

Meet the Biotech Swiss National Start-up Team before their exclusive roadshow to Boston! Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex Boston. The program with a value of CHF 10,000 is offered free of charge to the winners thanks to the support of Debiopharm, EPF Lausanne, ETH Zurich, Kellerhals Carrard, Hansjörg Wyss, Novartis, Swiss Biotech Association, and VISCHER. Join us as we showcase the innovative spirit and potential of these exceptional start-ups.

Moderation: **Ekaterina Koleva**, Program Manager, Venturelab

17:45 Venture Leaders Biotech introduction

17:50 Allegria Therapeutics

18:10 TissueLabs

17:54 Well Science

18:14 EVIIVE

17:58 Ymmunobio

18:18 inSEIT

18:02 Adoram Therapeutics

18:22 Shape Biopharmaceuticals






18:06 KYLYS AESTHETICS

18:26 Voting and closing address

## Clinical stage companies

Presented by
















Time	Company	Room Samarkand
14:10	Celonic	
14:30	Vaccentis	
14:45	Santhera Pharmaceuticals	
15:00	Muvon Therapeutics	
15:15	Endogena Therapeutics	
15:30	Azafaros	
15:45	AB2 Bio	
16:00	Break	
16:15	Gnubiotics	
16:30	Canvirex	
16:45	Stalcla	
17:00	FatiAbGen	

Moderation: **Georg Blaser**, Celonic Group

## Advanced biotech companies

Presented by **Lonza**

Time	Company	Room Osaka
14:30	Lonza	
14:45	Basilea	
15:00	HealSun Biopharm	
15:15	AlphaMol Science	
15:30	Labcorp	
15:45	Cytiva	
16:00	Break	
16:15	Qiagen	
16:30	Elsevier	
16:45	The Jackson Laboratory	
17:00	IPS-Integrated Project Services	
17:15	Stämm	
17:30	Nerviano Medical Sciences	
17:45	Inizio	

Moderation: **Sven Bieli**, Lonza

See all information on the presenting companies here →



# Panel discussions

Presented by **14:30-15:15 Panel 1****Room Sydney**

## Driving clinical development during challenging financial times

Are financial challenges hindering your clinical development journey? How to secure funding in today's evolving landscape?

Amidst a dynamic financial environment impacting drug development across the globe, companies need to make the right decisions in order to thrive.

Join our session to learn from the experiences of experts from venture capital, biotechnology, and the contract research space, who will deliver actionable insights to help you lead through challenging times.

Moderation: **Oren Cohen**, Chief Medical Officer and President of Clinical Pharmacology, Fortrea

Panelists:

**Erik van den Berg**, CEO, Memo Therapeutics

**Daniela Schmitter**, Head of Clinical Operations, Alentis Therapeutics

**Marc Lohrmann**, Managing Partner, Vesalius Biocapital III

**Alison Foster**, VP Strategic Delivery and Growth, Fortrea

Presented by **15:30-16:15 Panel 2****Room Sydney**

## How regulators can best support innovation

Regulatory agencies play a pivotal role in supporting Biotech R&D SMEs in their preparation of clinical trials and effective delivery of innovative and reliable therapies to patients. Engaging early with Biotech R&Ds increases the chances of complying with regulatory requirements. Experiences and available tools are discussed.

Moderation: **Monika Jones**

Panelists:

**Philippe Girard**, Vice Director, Head of Medicinal product licences and surveillance, SWISSMEDIC Swiss Agency for Therapeutic Products

**Daniel Meirelles Fernandes Pereira**, Director, Member of the Board of Directors, ANVISA Brazilian Health Regulatory Agency

**Bettina Ernst**, CEO, Bernina Bioinvest & Innosuisse Innovation Council

**Ulf Grawunder**, Managing Partner, Viopas Venture Consulting, Basel, Switzerland; CEO, T-CURX, Würzburg, Germany

Presented by **16:30-17:15 Panel 3****Room Sydney**

## Achieve initial market access in Switzerland.

Switzerland is a recognized research location for pharmaceutical innovations, with many start-ups developing new products. Is initial market authorization worth it in Switzerland? The most essential and mandatory prerequisites for Switzerland as a biotech start-up innovation location are new additional and fast authorization channels involving patients and medical doctors. Join and discuss with us.

Moderation: **Stephan Klapproth**, Entrepreneur, journalist and former TV moderator, What's your Point

Panelists:

**Carlos Beat Quinto**, Member of the FMH central board

**Peter Halbherr**, Chairman and General Manager, InnoMedica

*Further panelists are announced on [www.swissbiotechday.ch](http://www.swissbiotechday.ch)*

Presented by  **17:30-18:15 Panel 4****Room Sydney**

## Investments into global HC systems

HC investments in low- and middle-income countries are engines of economic growth, social equity, and political stability. The Swiss life sciences industry, together with Swiss government organizations, academic institutions, and Swiss-based non-profit organizations, plays a key role in HC programs around the world. To further maximize the ROI of HC spending in LMICs, a more synchronized approach among Swiss stakeholders is needed.

Moderation: **André Guedel**, President Swiss African Business Circle, Head BD KPMG

Panelists:

**Lutz Hegemann**, President, Global Health & Sustainability, Novartis

**Michael Altorfer**, CEO, Swiss Biotech Association

**Jörg Schläpfer**, Head Intl. Relations, Swissmedic

**Sitara Merchant**, CEO, Swiss Capacity Building Facility (SCBF)



Presented by **14:30-15:15 Panel 5**

Room Rio

**ADCs & beyond**

Antibody-Drug Conjugates (ADCs) are currently among the most promising drug classes in oncology due to their ability to deliver cytotoxins to specific tumor sites, combining the selectivity of antibodies and the efficacy of chemotherapeutic drugs. What will be the next generation of ADCs? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? This panel would like to explore on those topics.

Moderation: **Ulf Grawunder**, Managing Partner, Viopas Venture Consulting, Basel, Switzerland; CEO, T-CURX, Würzburg, Germany

Panelists:

**Eric Lu**, Senior Director Business Development, WuXi XDC

**Frederic Levy**, CSO, Debiopharm

**Christoph Schäfer**, CEO, CIS Pharma

**Philipp Spycher**, CSO, Araris Biotech

**Carl Deutsch**, CSO, NBE-Therapeutics, Boehringer Ingelheim

Presented by  **15:30-16:15 Panel 6**

Room Rio

**Innovate & educate: sparking biotech's future**

The panel will explore key strategies and initiatives aimed at fostering innovation and education within the biotechnology sector:

- Nurturing a business mindset in scientists.
- Improving biotech education to meet industry needs.
- Connecting academia, industry and start-ups to bridge the gap between research and commercialization

Moderation: **Nathalie Rowell**, CEO, VirdisGroup

Panelists:

**Annette Mollet**, Managing Director, European Center of Pharmaceutical Medicine and Head Education and Training, University of Basel

**Mark Illi**, Co-Director, ITEM

**Aksana Labokha**, CEO, Rejuveron

Presented by **16:30-17:15 Panel 7**

Room Rio

**The quest for further improving the framework conditions for biotech companies**

Panelists from the formed SBA Legal Tax & Accounting Chapter will share some key points of the Swiss framework conditions and more efficient ways to achieve the goals of biotech companies. Active participation of the audience is welcome. Topics include: Legal and tax challenges with fundraising using hybrid instruments; intra-group financing and valuation questions of ESOPs

Moderation: **Matthias Staehelin**, Lead Partner Life Sciences, VISCHER

Panelists:

**Dieter Gericke**, Head Corporate / M&A, Co-Head Healthcare, Homburger

**Frederik Schmachtenberg**, Partner EY Life Sciences, Ernst & Young

**Fabienne Limacher**, Partner, Tax, Walder Wyss

Presented by **17:30-18:15 Panel 8**

Room Rio

**Drug discovery for rare diseases: from genes to treatments**

Five experts in preclinical rare disease research will discuss the impact of recent technological and scientific advancements on rare disease drug development. The panelists come from diverse backgrounds, including academic research, preclinical, and clinical development, and each of them will offer a unique perspective on a range of arguments, from disease modeling to regulatory requirements.

Moderation: **Alexandre Reymond**, Professor, Center for Integrative Genomics of the University of Lausanne

Panelists:

**Laurent Bogdanik**, Associate Director, Preclinical Services – Neurology and Gene Therapy

**Manolo Bellotto**, Chief Strategy Officer and General Manager, Gain Therapeutics

**Harald Petry**, CEO, Avrion Therapeutics

**Djordje Filipovic**, CEO, AB2 Bio



Presented by  

**14:30-15:15 Panel 9**

Marriott Hotel

**Are current incentives to promote drug innovation in healthcare sustainable?**

In the context of rising expectations and heightened budgetary pressures, it is crucial to delve into the significance of implementing the right incentives to foster continued research, development, and commercialization for innovative medicines. With speakers from different parts of the healthcare sector, this panel will discuss the tensions in the system and the role of all stakeholders in addressing these and making innovation a reality for patients.

Moderation: **Christophe Hilbert**, Director, European Reimbursement and Access, Incyte Biosciences International

Panelists:

**Hervé Lamarque**, Division Vice President, Head of Value Access Pricing & Business Development Europe, Incyte Biosciences International

**Rosmarie Pfau**, Founder & President, lymphome.ch

**Elisabeth Roider**, Physician scientist, Universitätsspital Basel

**Andreas Wildi**, attorney-at-law, Partner, Walder Wyss

Presented by 

**15:30-16:15 Panel 10**

Marriott Hotel

**Maintaining funding flexibility to grow value**

Capital markets are opening up in 2024 for biotech after two dry years, and a few Swiss companies are considering public listing. Is it the best way to grow value? What paths can a late-stage biotech consider? Join us to discuss the opportunities and challenges an IPO brings, and exchange experience in the Swiss biotech ecosystem.

Moderation: **Peter Mozerov**, Senior Manager, KPMG

Panelists:

**Reto Näf**, Chairman of the BoD, Topadur Pharma

**Dario Eklund**, CEO, Santhera Pharmaceuticals

**Sascha Bucher**, Co-Founder and Partner, Forty51 Ventures

**Valentin Piëch**, PhD, Managing Partner, Biomed VC

Presented by 

**16:30-17:15 Panel 11**

Marriott Hotel

**Life Science Cares Switzerland – bringing hearts and minds together**

Life Science Cares Switzerland (LSCS) is a newly founded organization which brings together the Life Science Community and local non-profit organizations to build bridges for people with limited opportunities by breaking the vicious circle of poverty and inequality in Switzerland. Its purpose is equal access to education and opportunities for all. The panel puts the focus on why this matters and shares insights from the work of Life Science Cares USA.

Moderation: **Seth Lewis**, Senior Vice President Investor Relations and Strategy, Molecular Partners

Panelists:

**Patrick Amstutz**, CEO Molecular Partners & President Swiss Biotech Association

**Isabel Dalli**, Global Head Sponsoring and Donations & Founder LSCS, Novartis

**Dorothea Bergler**, Head of Partner and Institutional Engagement, Schweizerisches Rotes Kreuz

**Div Gupta**, Partner, Cooley, Board of advisors of Life Sciences Cares NY

Presented by 

**17:30-18:15 Panel 12**

Marriott Hotel

**Seeking payer-relevant input into your development plan: Focus the development effort to maximize commercial potential**

A strong scientific case is not enough. Maximizing commercial potential starts early and needs to be an integral part of successful development. Yet, many biotechs start (too) late. Explore strategies for efficient and effective development, enhancing asset value by integrating payer-relevant input. Gain insights from industry leaders and healthcare payers as they discuss ways to refine your approach and demonstrate value that convinces payers and investors.


Moderation: **Prateet Minhas**, Managing Director, Syneos Health Consulting

Panelists:

**Laurent Massuyeau**, CEO & Founder, IQone Healthcare

**Marina Faiella**, Head Forecasting & Analytics, BeiGene

**Mathias Flume**, Head of Department, Kassenärztliche Vereinigung

Presented by 

16:30-17:15 Panel 13

Room Montreal

**More with less: Expert insights on how process intensification can be used to achieve affordable and sustainable biologics manufacturing**

Under the light of changing paradigms in the biopharmaceutical industry more and more focus is given on increasing the productivity, lowering the costs and speeding up the time to clinic. Can an intensified approach towards biopharmaceutical manufacturing shape the future of the whole industry? Gain crucial insights from different viewpoints by attending the panel discussion with experienced industry leaders out of different functions, positions and modalities in the market.

Moderation: **Uwe Gottschalk**, Operating Partner, Keensight Capital

Panelists:

**Eduard Ayuso**, Chief Technology Officer, Siegfried Dinamiq**Georg Blaser & Samanta Cimitan**, VP Biologics Development Center & CEO, Celonic**John Manneke**, Global Category Manager Drug Substance, Roche**Thomas Villiger**, Professor of Bioprocess Technology, FHNW[See all information on the panel discussions here →](#)

# Global Village

Presented by  Swiss Biotech Association 

Global Village

Room San Francisco

**Welcome to the Global Village at the Swiss Biotech Day 2024 - The power of international collaboration.**

**The Global Village is an effective platform hosted by the Swiss Biotech Association in partnership with other Swiss organizations who engage in worldwide networking and international collaboration in biotech and life sciences.**

The Global Village provides a dedicated offering for national and regional delegations from foreign biotech clusters who wish to develop and strengthen long-term and sustainable business ties and collaborations with various stakeholders of the Swiss biotech ecosystem. The Global Village platform aims at continuous and sustainable collaboration, concrete action plans for collaboration with impact and collaboration with mutual benefit for all involved.

Since the platform was initiated in 2022 many delegations from North and South America, Asia, Australia, and Europe have engaged in the Global Village and outlined successfully essential steps to move collaborations forward.

This year the Global Village is joined by a record number of 17 delegations. The conference program offers a multitude of opportunities and all Swiss Biotech Day participants are welcome to engage with international delegations:

- Meet and engage with delegation members at their booth in the Global Village area (p. 20-23 & 45)
- Witness roundtable discussions exploring opportunities for collaboration (p. 24-25)
- Join a dedicated pitching session with companies from international delegations (p. 42)
- Meet all members of delegations at the International Reception on Monday 18:00
- Take advantage of the final opportunity to meet delegations at the market place on Tuesday 16:00

[See all information of the Global Village here →](#)

# Global Village

Presented by 

## Delegation of the Netherlands

**Roundtable discussion:** Monday, April 22, 14:30 – 15:30

**Participating companies:**  
 Amarna Therapeutics, Basic Pharma Holding, Biotactical, Biotech Booster, Catherinn, Digi.Bio, Genewity, Glycomscan, HALIX, Health Holland, InnoGI Technologies, Leiden University Medical Center, Lygature, Medace, Novartis, NTrans Technologies, Oncode Accelerator, PPI HC, RegMed XB, RIBOPRO, Roche NL, Scinus Cell Expansion Netherlands, TNO - Peregrion, University Medical Center Utrecht, VitroScan, Embassy of the Kingdom of the Netherlands, Netherlands Enterprise Agency

Presented by 

## Delegation of Orgeon

**Roundtable discussion:** Monday, April 22, 15:45 – 16:15

**Participating companies:**  
 Business Oregon, Oregon Bioscience Association, Augmented, Dextronix, Rewire AI

Presented by 

## Delegation of Spain

**Roundtable discussion:** Monday, April 22, 16:30 – 17:00

**Participating companies:**  
 3P Biovian, Almirall, AseBio, Basque Health Cluster, BeCytes Biotechnologies, bFlow, Biobide, Bioga, Bioingenium, CZ Vaccines, Diversa Technologies, Fundación Medina, GalChimia, Gate2Brain, Innoprot, Libera Bio, ONIRIA THERAPEUTICS, Oryzon, SPECIFIC PIG, TAD

Presented by 

## Delegation of Greece

**Roundtable discussion:** Monday, April 22, 17:15 – 17:45

**Participating companies:**  
 PhosPrint, National Centre For Scientific Research Demokritos, Hellenic Biocluster, Pharmassist CRO, Protavio, Bioemtech

Presented by 

## Delegation of Canada

**Roundtable discussion:** Monday, April 22, 17:15 – 17:45

**Participating companies:**  
 Government of Canada – Trade Commissioner Service, Q&C Services, Hermay Labs Corporation, Myomar Molecular, Eyam Vaccines and Immunotherapeutics, Precision NanoSystems, Dalriada Drug Discovery, Life360 Innovations, Nimble Science, Future-Fields, PolyAnalytics

Presented by 

## Delegation of Japan

**Roundtable discussion:** Tuesday, April 23, 12:15 – 12:45

**Participating companies:**  
 Swiss Business Hub Japan / Embassy of Switzerland in Japan, Gellycle, Maruho Deutschland, Astellas Pharma Europe, Hirata Corporation, Terumo Corporation, Daiichi Sankyo, Syncrest, Genesis Healthcare, Kissei America, Otsuka Pharmaceutical Europe, NOF Corporation, Eisai, Senju Pharmaceutical

Presented by 

## Delegation of Rhineland-Palatinate

**Roundtable discussion:** Tuesday, April 23, 12:15 – 12:45

**Participating companies:**  
 Ministry of Economic Affairs, Transport, Agriculture and Viniculture Rhineland-Palatinate, BioVation RLP, biomindz, Chamber of Commerce and Industry for Rheinhessen, Chamber of Foreign Trade Switzerland

Presented by 

## Delegation of Hong Kong / China

**Roundtable discussion:** Tuesday, April 23, 13:00 – 13:30

**Participating companies:**  
 HEC Lausanne, iCANX, InvestHK, HKTDC, HKEX, Quant Biomarkers

Presented by 

### Delegation of Brazil

**Roundtable discussion:** Tuesday, April 23, 13:45 – 14:15

**Participating companies:**  
Gcell, Synvia, ICL, Inovatie, Intrials, Biolab, Parque Tecnológico de Campina Grande, Fiocruz, Libbs, ANVISA Brazilian Health Regulatory Agency, Sindusfarma, MedNova Consulting

Presented by   

### Delegation of Taiwan

**Roundtable discussion:** Tuesday, April 23, 13:45 – 14:15

**Participating companies:**  
TaiwanBio, Biomedical Translation Research Center (BioTreC), Bora Biologics, KriSan Biotech

Presented by 

### Delegation of South Korea

**Roundtable discussion:** Tuesday, April 23, 14:30 – 15:00

**Participating companies:**  
KOTRA (Korea Trade-Investment Promotion Agency), VSPHarmTech, RadaHaim, AmoLifeScience, ILIAS Biologics, Prestige Biologics, Portrai, Rokit Healthcare, AICloud, Healthibuddy, Foretell My Health, Peptide, Swiss Business Hub Korea, Pohang City

Presented by 

### Delegation of France

**Roundtable discussion:** Tuesday, April 23, 14:30 – 15:00

**Participating companies:**  
AlphaOnco Swiss, CellProthera, ARaymondLife, Ciloa, Keyrus

Presented by 

### Delegation of India

**Roundtable discussion:** Tuesday, April 23, 15:15 – 15:45

**Participating companies:**  
Swiss Business Hub India, Swati Spentose, Persistent Systems, Metastop Solutions, Centella AI Therapeutics, Presciences Insilico, Avinya Biotech, SICC, Veeda CR

Presented by  

### Delegation of Bavaria

**Roundtable discussion:** Tuesday, April 23, 15:15 – 15:45

**Participating companies:**  
Bio-M Biotech Cluster Development, FGK Clinical Research, Cfm Oskar Tropitzsch, Cortex Discovery, Iris Biotech, Velvio

Presented by    

### Delegation of Italy

**Participating companies:**  
Istituto Biochimico Italiano G. Lorenzini, Nerviano Medical Sciences, Menarini Biotech, DIAMANTE Healthcare, Accelera, NerPharMa

Presented by  

### Delegation of Poland

**Participating companies:**  
A4BEE, BIOTON, Bioforum Association, CLINMARK, DICELLA, ExecMind, Nencki Institute for Experimental Biology PAN, City of ŁÓDZ, MEDICAL INVENTI, ŁUKASIEWICZ RESEARCH NETWORK – Technology Institute of Lodz, Polish Agency Investment & Trade Agency (PAIH), SIGEON IP, SYVENTO

Presented by   

### Delegation of Saxony

**Participating companies:**  
AIREA – The Airport Region in Central Germany, IMG (Investitions- und Marketing-gesellschaft Sachsen-Anhalt), biosaxony, Wirtschaftsförderung Sachsen WFS, Weinberg Campus, Life Science Sachsen-Anhalt, Oncotec Pharma Produktion, Biotype

## Roundtable discussions

Please join us for Roundtable discussions, aiming to facilitate partnerships and connect international representatives with the Swiss biotech industry for research, corporate collaborations, policy-making and investments.

Monday 22 <sup>nd</sup> April	Roundtable 1 San Francisco (stage)	Roundtable 2 San Francisco
14:30-15:30	<b>The Netherlands</b> Building strategic bridges for innovative therapy development	
15:45-16:15	<b>Oregon</b> Explore long-term collaboration opportunities between Oregon's biosciences community and Swiss biotech ecosystem	
16:30-17:00	<b>Spain</b> Sustainable collaboration between Spanish and Swiss biotech ecosystems	
17:15-17:45	<b>Canada</b> Biotech innovation & collaboration in Switzerland and Canada	<b>Greece</b> Swiss-Greek biotech opportunities: Early stage innovation acceleration & collaboration in clinical trials

Tuesday 23 <sup>rd</sup> April	Roundtable 1 San Francisco (stage)	Roundtable 2 San Francisco
12:15-12:45	<b>Japan</b> Japanese and Swiss biotech ecosystem collaboration	<b>Rhineland-Palatinate</b> Building a biotech cluster today - successful recipes, added value for stakeholders, economic and social impact
13:00-13:30	<b>Hong Kong China</b> Biotech ecosystem collaboration	
13:45-14:15	<b>Brazil</b> Facilitating investments, licensing and clinical trials: Brazilian-Swiss biotech opportunities	<b>Taiwan</b> Essential tools in process science to ensure safety and potency for biologics development
14:30-15:00	<b>South Korea</b> Fostering bio industrial R&D cooperation between Korea and Switzerland	<b>France</b> Comparative analysis on financing opportunities between Switzerland and France: private/public funding, public incentives and cross-border investments
15:15-15:45	<b>India</b> Opportunities created by the Trade and Economic Partnership Agreement signed between Switzerland and India in the biotech sector	<b>Bavaria</b> From cutting-edge innovation to strong industrial partnerships between Bavaria and Swiss biotech ecosystems

See all information of the Global Village here →



# Pitching sessions

Presented by  Swiss Biotech Association

09:00-09:45 Pitch

Room Singapore

## Next generation organ-on-chip & organoids

In recent years, the pharma/biotech industry has recognized the importance of seeking viable alternatives to traditional animal testing. This shift has led to advancements in the development of innovative technologies that include organoids and organs-on-a-chip. These cutting-edge solutions have paved the way for a more ethical and efficient approach to drug development. The pitching session will present innovative companies and one innovation centre developing disruptive solutions.

Moderation: **Madhu Nag**, InSphero

Jury: **Zoë Johnson**, CSO & CDO, M:M Bio | **András Incze**, Akceso Advisors | **Matteo Cornaglia**, Nagi Bioscience

09:00 Introduction

09:05 InSphero 09:25 Prometheus Life Technologies

09:10 PreComb Therapeutics 09:30 BioFi

09:15 FluoSphera 09:35 abc biopply

09:20 CSEM 09:40 Voting and closing address

Presented by  Swiss Biotech Association  Antion Biosciences

09:00-09:45 Pitch

Room Sydney

## Recent developments and future avenues in cell & gene therapies

Cell & Gene Therapy (CGT) are exciting therapeutic modalities which bring us closer to our goal of curing disease. This CGT pitching session will showcase innovative companies at various stages of development. The focus will delve into three key facets of deploying CGT to address diverse medical needs: (i) gene therapy for genetically defined disorders, (ii) recent strides in CGT within immune-oncology, and (iii) advancements in tackling autoimmunity.

Moderation: **Markus Kalousek**, BioGeneration Ventures

09:00 Introduction

09:04 Avrion Therapeutics 09:20 Advesya

09:08 TiGen Pharma 09:24 CSL Behring

09:12 T-CurX 09:28 Novartis

09:16 Antion Biosciences 09:32 J&J

09:36 Voting and closing address

Presented by  Timeline

09:00-09:45 Pitch

Room Rio

## Innovative companies in healthspan and longevity

Join us for an exciting showcase session with cutting-edge companies in healthspan and longevity. We have selected a cohort of start-ups and scale-ups with innovative science-based solutions tackling meaningful problems in the space. You will have an opportunity to discover pioneers from different sectors including nutrition, beauty, therapeutics, smart devices and to connect with the CEOs and founders.

Moderation: **Federico Luna**, CMO, Timeline

09:00 Introduction

09:05 Timeline 09:20 Senisca

09:10 Vandria 09:25 Epiterna

09:15 Senbiosys 09:30 Rejuveron senescence therapeutics

09:35 Voting and closing address

Presented by  Curie.Bio

09:00-09:45 Pitch

Marriott Hotel

## Investors pitch to the audience

Are you tired of pitching to investors? What if investors pitched themselves to you? In this session, we do exactly that. Join us to hear a range of biotech investors discuss their approach for funding the best therapeutic ideas. We'll chat about how we evaluate ideas and help our portfolio companies discover and develop life changing medicines for patients.

Jury: **Dominik Hartl**, CMO, Granite Bio | **Anja Harmeier**, CEO, Rewind Therapeutics

09:00 Introduction

09:05 Novartis Venture Fund 09:26 Digitalis Ventures

09:12 Pureos Bioventures 09:33 Curie.Bio

09:29 Nextech Invest 09:40 Closing address



## Plenary session II

### Plenary session II

Room Montreal

Moderation: **Monika Jones**

#### 10:00- Decoding Swiss Biotech – the investors perspective

**12:00** **Seth Lewis**, Senior Vice President Investor Relations, Communications and Strategy, Molecular Partners  
**Francesco De Rubertis**, Co-Founder and Partner, Medicxi  
**Otello Stampacchia**, Managing Director, Omega Funds  
**Matthias Fehr**, Head Private Equity, HBM Partners  
**Nicholas Riddle**, Managing Director Healthcare Investment Banking, JP Morgan

#### Pharma partnering panel

**Matthias Müllenbeck**, SVP, Head of Global Business Development & Alliance Management, Merck KGaA  
**Richard Girling**, Partner, Centerview Partners  
**Frances Stocks Allen**, Partner, Cooley  
**Brad Robling**, Vice President, Eli Lilly and Company

#### Site Selection Report

**André Guedel**, Head International Business Development, KPMG

#### Swiss Biotech Report

**Frederik Schmachtenberg**, Partner, EY

#### Swiss Biotech Success Stories Awards

**Luca Bolliger**, jury president



## Emerging biotech companies

Presented by **PUREOS BIOVENTURES**

Time	Company	Room Singapore
13:00	NovaGo Therapeutics	
13:15	AdRegeneer	
13:30	Osasuna Therapeutics	
13:45	Amphilix	
14:00	Adoram Therapeutics	
14:15	Tenpoint Therapeutics	
14:30	Break	
14:45	Phialogics	
15:00	Mysthera Therapeutics	
15:15	AC Bioscience	
15:30	ATLyphe	
15:45	Leman Biotech	
16:00	Pilatus Biosciences	
16:15	Cimeio Therapeutics	
16:30	Avrion Therapeutics	

Moderation: **Ximing Ding & Butrint Aliu**, Pureos Bioventures



## Clinical stage companies

Presented by



Time	Company	Room Sydney
12:40	Celonic	
13:00	Molecular Partners	
13:15	4Teen4 Pharmaceuticals	
13:30	ImmunOs	
13:45	Addex Therapeutics	
14:00	Eli Lilly	
14:15	GeNeuro	
14:30	Break	
14:45	Topadur Pharma	
15:00	Cutiss	
15:15	Ariceum Therapeutics	
15:30	Oculis	

Moderation: **Georg Blaser**, Celonic Group

## Advanced biotech companies

Presented by **LONZA**

Time	Company	Room Osaka
13:00	FoRx Therapeutics	
13:15	Johnson & Johnson Innovation	
13:30	Scandion Oncology	
13:45	Selvita	
14:00	LS Instruments	
14:15	Trialize	
14:30	Lonza	
14:45	EspeRare Fondation	
15:00	Maiwald	
15:15	IKA-Werke	
15:30	Commissioning Agents International (CAI Suisse)	
15:45	QBDC	
16:00	Ciloa	
16:15	BIO4 Campus	

Moderation: **Dominik Wegmann**, Lonza

See all information on the presenting companies here →



# Panel discussions & Pitching sessions

Presented by



## 12:00-12:45 Panel 14

Room Osaka

### Microbiome therapies, perspectives and outlook one year after first market launch

The microbiome is a rapidly advancing field. The first microbiome-based products opened up new commercial opportunities. This panel is designed as an educational piece for a broad audience discussing true drug development and outlook in the field. Switzerland is a global leader in microbiome innovation, with world-class research institutions and companies driving progress in the field to develop new treatments.

Moderation: **Isma Hachi**, IQVIA

Panelists:

**Gabriel Leventhal**, PharmaBiome

**Casper Johansen**, Ferring Pharmaceuticals

**Alessandra Calabrese**, OM Pharma

**Gemma Henderson**, Bacthera



See all information on the panel discussions here →

Presented by



## 12:15-13:00 Pitch industrial biotech

Room Samarkand

### Cooperating and partnering to address critical environmental challenges through industrial biotechnology

Industrial Biotechnology (IB) allows for more energy-efficient and sustainable manufacturing processes as well as creating opportunities for abating pollution, using waste and creating new products. It underpins a circular economy, sustainable chemicals industry and can help to protect scarce natural resources. It is likely to impact many aspects of everyday life through new biobased products and processes with far reaching and disruptive impacts. This session starts with the pitches from a number of pioneering early stage Swiss companies. The pitches serve as a basis for an corporate and investor panel sharing their views on how these companies can serve as case studies for the development of the sector.

Moderation:

**Anne Marie de Jonge-Schuermans**, Board Member of the Swiss Biotech Association

**12:15** Introduction

**12:18** Agrosustain

**12:38** NeoCarbons

**12:23** Inofea

**12:43** Inseit

**12:28** Planetary

**12:48** CellX Biosollutions

**12:33** Lock and Key Biosciences

**12:53** Voting and closing address

## 13:00-13:45 Panel 15: Industrial biotech

Moderation:

**Anne Marie de Jonge-Schuermans**, Board Member of the Swiss Biotech Association

Panelists:

**Viviane Monges**, EuroAPI, Board of Novo Holdings

**Massimo Nobile**, CEO Swiss Biotech Center

**Martin Riediker**, Independent investor, Board member for multiple companies including Inofea

**Andreas Taglieber**, Director of R&D Biotechnology, DSM-Firmenich

**Vivek Dogra**, Co-Founder and General Partner, Defossilisation Development Fund

Presented by **14:00-14:45 Panel 16****Room Samarkand****Radioligand therapies – How Switzerland is enabling innovation in nuclear medicine**

For over a decade, Swiss companies and scientists have been at the forefront of nuclear medicine. As the field of radiotherapeutics continues to grow, how will Switzerland continue to contribute and lead in this next era of innovation for cancer patients? Join us live as we discuss!

Moderation: **Ken Herrmann**, Chair, Department of Nuclear Medicine, Universitätsmedizin Essen

Panelists:

**Emanuele Ostuni**, CEO, Artbio

**Roger Schibli**, Head of Center for Radiopharmaceutical Sciences, PSI

**Daniel Steiner**, SVP Research & Technology, Molecular Partners

**Jeevan Virk**, RLT Therapeutic Area Strategy Head, Novartis

Presented by **15:00-15:45 Panel 17****Room Samarkand****Pioneering partnerships: Biotech alliances to patient impact**

The CSL theme at Swiss Biotech Day 2024 encapsulates the event's focus on fostering strategic alliances across the biotech landscape. Featuring distinguished panelists including Amanda Gett-Chaperot, Eve Williamson, Maria Crespo, and Emmanuelle Lecomte Brisset, we will delve into the nuances of venture creation, innovation scouting, and the development pathways that lead from early-stage research to market-ready solutions.

Moderation: **Adrian Zuercher**, Vice President, Research EU & Head Plasma Protein Research, CSL

Panelists:

**Amanda Gett-Chaperot**, Partner, Kurma Partners

**Eve Williamson**, Vice President, Global Head of Business Development, CSL

**Maria Crespo**, Director, Bioprocess Development, CSL

**Emmanuelle Lecomte Brisset**, Senior Vice President, Head Global Regulatory Affairs, CSL

Presented by **16:00-16:45 Panel 18****Room Samarkand****Scaling up precision medicine with AI-driven approaches**

Precision oncology is driving a paradigm shift in drug development and routine clinical practice, with the integration of AI promising to add unprecedented levels of accuracy and efficacy. We will explore the practical applications of AI, discussing challenges and collaborative strategies to scale up access, and highlight the need for standardization of AI-driven approaches. Additionally, we will evaluate how these approaches can support clinical decision-making.

Moderation: **Guillaume Cettou**, Global Head of Data Partnerships, SOPHiA GENETICS

Panelists:

**Michael Frank**, Director Digital Health, Business Development, Memorial Sloan Kettering Cancer Center

**Benjamin Kasenda**, Senior Consultant Medical Oncologist, Universitäts-spital Basel (USB)

**Serafino Pantano**, Head of Translational Medicine, ADC Therapeutics

**Gabriele Gut**, Senior Assistent at the Clinical for Medical Oncology and Haematology, University Hospital Zürich

Presented by   **12:15-13:00 Panel 19: Lab automation**

Room Rio

**Bio-Processing: The Next Generation. How to meet the challenges of new therapeutics, cost pressure and big data?**

During this session we will delve into some of the innovative strategies brought forward by key players in the field to face the multifaceted difficulties dictated by the advent of novel therapies, the need to implement cost-effective solutions, and the hassles as well as opportunities driven by the generation & harnessing of big data.

Moderation: **Christian Walter**, Managing Director, Verein Toolpoint for Lab Science

Panelists:

**Daniel Egger**, Global Marketing Director Process Analytics, Hamilton Bonaduz**Bachir El Debs**, Director, High Throughput Biologics R&D, Lonza**Samantha Paoletti**, Head of Research and BD Life Science Technologies, CSEM**Andreas Koch**, Head of Key Account Management, Securecell**13:00-13:45 Pitching Lab automation****Lab automation, diagnostics and analytics**

Join us for a vibrant second edition of the pitching competition linked to the Swiss Biotech Association Chapter *Lab automation, diagnostics and analytics!* The selected cohort of start-ups will showcase their disruptive technologies stemming from advancements in laboratory science and automation, novel screening pipelines and platforms, as well as integrated diagnostics and patient stratification solutions.

Moderation: **Samantha Paoletti**, Head of Research and BD Life Science Technologies, CSEM

Jury: **Alexandra Vallon Eberhard**, Senior Director – CTO, Global Strategy & Partnering Roche Diagnostics | **Miro Venturi**, President DIAMANTE Healthcare Consulting, Switzerland & Operating Partner ARCHIMED Group | **Shayesteh Fürst-Ladani**, CEO, Luminance Health | **Daniel Egger**, Global Marketing Director Process Analytics, Hamilton Bonaduz

**13:00** Introduction**13:03** Limula **13:21** Nagi Bioscience**13:06** Navignostics **13:24** Isospec Analytics**13:09** Maven Health **13:27** NexMR**13:12** TheraME! **13:30** Oryl photonics**13:15** ONTRACK Biomedical **13:33** Ceidos**13:18** Adaptyv Biol **13:36** Voting and closing addressPresented by  **14:00-14:45 Panel 20**

Room Rio

**Talent Trek: Biotech's needs, challenges and opportunities**

To successfully grow a biotech company, it needs at least three components: an innovative idea, solid financing, and an excellent team. The focus of this panel is on how to attract, retain, and develop a top team. Our panelists will share success stories and challenges, provide insights, and answer questions.

Moderation: **Natasha Konstantinova**, Head of Talent and Academy, Swiss Biotech Association

Panelists:

**Sophie Romann**, Director of Human Resources International, Mirum Pharmaceutical**Nicholas Barbet**, COO Cellerys**Karolina Jarosińska**, Managing Director, ExecMind**Peter Kilian**, CEO, CTC Resourcing SolutionsPresented by  **15:00-15:45 Panel 21**

Room Rio

**AMR: From awareness to action. The time is now to invest.**

Building on “Beyond Antibiotics: The Reckoning of Antimicrobial Resistance, A New Biological Frontier”, experts address one of the biggest global challenges of our time. Covering everything from the duality of oncology & infectious diseases, sustainable & scalable manufacturing, attracting & retaining global expertise and rethinking investment & commercial incentives, the session will provide actionable insights into practical steps the industry must take to combat AMR.

Moderation: **Guillermo Tramontin**, Principal Consultant, Cavenagh Health

Panelists:

**Najj AIsayed**, Global Therapeutic Area Head – Infectious Diseases, Menarini Group**Morgane Vanbiervliet**, Market Intelligence & Business Development Manager – Infectious Diseases, Debiopharm International**Yann Ferrisse**, Director, Business Development & Partner Engagement, Global Antibiotic R&D Partnership (GARDP)**William Burns**, Board Chair, AMR Action Fund

Presented by **16:00-16:45 Panel 22****Room Rio****Exploring the power of exosomes: cutting-edge research and potential clinical applications**

Exosomes, as a nexus of biotech innovation and healthcare, pose unique opportunities and challenges from regulatory, and manufacturing, to market integration. This panel will explore the collaborative pathway for stakeholders across the spectrum, from investors to big pharma, to harness exosomes' potential in regenerative medicine, addressing scalability, safety, and accessibility to revolutionize patient care.

Moderation: **Philip Raeth**, CEO (Managing Director), palleos healthcare

Panelists:

**Troy Dale**, VP, Head Commercial – Strategic Partnerships Unit, Novartis**Irina Nazarenko**, Group Leader, University Medical Center Freiburg**Frank Plöger**, Chief Scientific Officer, Xlife Sciences**Agne Vaitkeviciene**, Co-Founder and CEO, Memel Biotech & COO, CurelinePartners    Presented by **12:15-13:00 Pitch health-tech****Marriott Hotel****Digital and health-tech**

Come witness the launch of the Swiss Biotech Association chapter Digital and Health-tech! Through this pitching competition you will peek into some of the groundbreaking technologies paving the path of the next healthcare revolution.

Moderation: **Jade Sternberg**, Senior Project Lead Digital Health, digitalswitzerland

Jury: **Nicolas Stalder**, Senior Investment Associate, Debiopharm Innovation Fund | **Sevan Antreasyan**, Partner, Lenz & Staehelin | **Andi Dyla**, Associate, Corporate Development, Roivant Sciences | **Lisa Falco**, Lead Data Consultant on AI for Health and FemTec Expert, Zühlke Engineering

**12:15** Introduction**12:19** Quant Biomarkers**12:39** Risklick**12:23** Moonlight AI**12:43** ancora.ai**12:27** Nexco Analytics**12:47** iCure**12:31** chAlron**12:51** MOD1**12:35** AiMorphous Health**12:55** VotingPresented by **13:00-13:45 Panel 23 health-tech****Marriott Hotel****How data, tech and AI can reimagine health systems**

How can digital technology re-engineer health systems from being reactive to becoming proactive and even predictive? Opportunities and challenges of shaping true health systems will be discussed at this session, bringing forward diverse perspectives through the intervention of visionary leaders.

Moderation: **Ann Aerts**, Head, Novartis Foundation

Panelists:

**Sevan Antreasyan**, Partner, Lenz & Staehelin**Katrin Cramer**, Director Personalized Health, Informatics Group, Swiss Institute of Bioinformatics**Vincent Lepreux**, Investment Principal, Debiopharm Innovation Fund

Presented by **14:00-14:45 Panel 24****Marriott Hotel****With a little help from my friends: How to establish and maintain your network in biotech – a CEO, a BD, and a VC perspective**

Having a good network is key for all players in the Biotech industry. How do you establish and nurture your network in Switzerland and abroad as a young professional? In this panel we will discuss how to build and maintain your network from the perspective of a CEO, a BD, and a VC.

Moderation: **Gabriela Ecco**, Senior Associate, +ND Capital  
**Anne Grahl**, Associate, Pureos Bioventures

Panelists:

**Jesus Baena**, BD&L Transactions Director, Novartis**Ksenija Pavletic**, Partner and COO, Jeito Capital**Samir Ounzain**, CEO and Co-Founder, Haya TherapeuticsPresented by **15:00-15:45 Panel 25****Marriott Hotel****Beyond oncology: Navigating the shifting landscape of biopharma innovation trends**

Are deal-making and investment trends revealing a shift away from “oncology as king” mentality? Companies are accessing innovation through new modalities outside of IO and other therapeutic areas are rising in popularity. The spotlight might be shifting towards innovation in inflammation, neurology, cardiometabolic and anti-infectives.

Moderation: **James Drew**, Consultant, Citeline

Panelists:

**Enrico Magnani**, Group Chief Strategy Officer, Helsinn**Simon T Russell**, Co-founder & Chief Commercial Officer, Synendos Therapeutics**Patrik Frei**, Founder and Chief Executive Officer, Venture ValuationPresented by **16:00-16:45 Panel 26****Marriott Hotel****How to strengthen the vital link to your investors in uncertain times**

In 2023, the negative financial environment combined with strong competition for funding resulted in a disconnect between investors and innovators, placing the entire value creation system at risk.

This panel will focus on practical solutions to restore the vital link between investors and innovators. The panelists will discuss how we can work together towards a more sustainable connection between biotech entrepreneurs and investors that helps navigate uncertainties.

Moderation: **Alexandra Wollersheim**, Partner, Transaction Advisory Services

Panelists:

**Ajla Hrle**, Head of Life Sciences, ATHOS*Further panelists are announced on [www.swissbiotechday.ch](http://www.swissbiotechday.ch)*

See all information on the panel discussions here →



# International pitching session

Presented by **13:00-14:00 Pitch Global Village****Room Montreal**

## Innovation beyond Switzerland: a selection of start-ups/emerging companies from international delegations

During this exciting pitching session, we are thrilled to present ten innovative start-ups and emerging companies from around the world that are making significant strides in the field of life sciences. These companies are revolutionizing the landscape with their cutting-edge technologies and solutions across various sectors within the life sciences industry, showcasing innovation, entrepreneurship, and a shared commitment to advancing healthcare and improving patient outcomes worldwide.

Moderation: **Maximilien Murone**, Swiss Biotech Association

Jury: **Zoë Johnson**, M:M Bio | **Kostas Kaloulis**, +ND Capital | **Natalia Novac**, Delin Ventures | **Andi Dyla**, Roivant Sciences | **András Incze**, Akceso Advisors

Companies:

Germany/Munich: **Velvio**

France: **Ciloa**

Netherlands: **Genewity**

South Korea: **Aicloud**

Canada: **Eyam Health**

Canada: **Myomar Molecular**

Canada: **Nimble Science**

Japan: **Syncrest**

Greece: **PhosPrint**



# SWISS BIOTECH DAY 2025

© Swiss Biotech Association

**May 5–6, 2025**  
Congress Center Basel

### Are you interested in increased visibility at the next Swiss Biotech Day?

We offer various sponsorship opportunities designed to promote your brand, products, services and build partnerships.

Contact us to discuss your ideas!

Meet our team today here at the BIOCOM booth #8a.


Or you can contact us at [marketing@biocom.de](mailto:marketing@biocom.de).

Host:




# Floor map

## 2<sup>nd</sup> floor



## 3<sup>rd</sup> floor




The **Marriott Hotel** (panel discussions 9-12 and 23-26) and **Hall 4.1** are located on the 1<sup>st</sup> floor between the entrance and the 2<sup>nd</sup> floor.

- Exhibitor booths
- Catering
- Media table
- Global Village
- Partnering tables
- Round table discussion
- Exhibitor service
- Sessions


# Floor map

1st floor





















- Exhibitor booths
- Partnering tables
- Partnering Help desk
- Poster presentation
- Catering
- Lounge
- Coffee bike
- Media table


















1st floor















# Exhibitors Foyer 2<sup>nd</sup> floor

Booth	Exhibitor
#1	Swiss Biotech Association 
#2	Friends of the Swiss Biotech Association   
#3	Exyte 
#4	Biopôle 
#5	Philip Morris Switzerland 
#6	A&M 
#7	MLM Medical Labs 
#8	BIOIVT 
#8a	BIOCOM 
#9	Supply Chain Operations 
#10	JACOBS 
#11	OPIS 
#12	Flow Technology 
#13	Charnwood Discovery 
#14	IPS-Integrated Project Services 
#15	Optimapharm 

Booth	Exhibitor
#16	ACROBiosystems 
#17	VolitionRx 
#18	Innosuisse 
#19	Nexco Analytics 
#20	Selvita 
#21	SAKK 
#22	Eurofins Discovery 
#23	Hamilton 
#24	CROss Alliance® 
#25	CRB 
#26	Microsynth 
#27	SGS Analytics Switzerland 
#28	YUMAB 
#29	KLIFO 
#30	KBI 
#31	Fortrea 

















Booth	Exhibitor	
#32	MyData-Trust	
#33	WuxiAppTec	
#34	Citeline	
#35	Almac Group	
#36	Northway Biotech	
#37	Asgard	
#38	LubioScience	
#39	DHL	
#40	PathoQuest	
#41	Ardena	
#42	Fasteris LifeScience / Genesupport	
#43	Tigermед	
#44	Honour Lab	
#45	Clinigen Group	
#46	Cytiva (Pall)	
#47	Miltenyi Biotec	
#48	Cencora PharmaLex	

















Booth	Exhibitor	
#49	IKA-Werke	
#50	Catalent	
#51	ZETA	
#52	ProtaGene	
#53	EuroscreenFast	
#54	Biotechnet Switzerland	
#55	CSEM	
#56	Hoffmann & Partner	
#57	Medicilon	
#58	SGS Quay Pharmaceuticals	
#59	Stemcell Technologies	
#60	Pharmadule Morimatsu	














See all information of the exhibitors here →



## Exhibitors Hall 4.1

Booth	Exhibitor	
#61	LabForce	
#62	Scilligence	
#63	ten23 health	
#64	Icosagen	
#65	Superlab Suisse	
#66	Techniconsult Group – Virtuarch	
#67	CrownBIO	
#68	Baccinex	
#69	Meditox	
#70	GxpManager	
#71	Labware	
#72	Biosynth	
#73	Eurofins CDMO	
#74	Sitem-Insel	
#75	ALPX	
#76	Advanced Clinical	




Booth	Exhibitor	
#77	PolyPeptide Group	
#78	Mod1	
#79	Senn Development	
#80	SecureCell	
#81	Quality Assistance	
#82	HealSun Biopharm	
#83	PULSE developed by EPIC SUISSE	
#84	Syneos Health	
#85	pci Pharma Services	
#86	Sino Biological Europe	
#87	GenomeScan	
#88	ExcellGene	
#89	Charles River Laboratories	
#90	Proteintech Europe	
#92	Syngene International	
#93	Latvian Institute of Organic Synthesis	

Booth	Exhibitor	
#94	Petrone Group/Euromed-Pharma	
#95	Wuxi Biologics/XDC	
#96	Qiagen	
#97	Ellab	
#98	Swiss Center for Musculoskeletal Biobanking (Balgrist)	
#99	Experimental Pharmacology & Oncology Berlin-Buch	
#100	CG CHEMIKALIEN	
#101	GTP Bioways	
#102	ETH Venture	
#103	Jubilant Biosys Limited	
#104	Luminex	
#105	Wemedoo	
#106	Celonic	

See all information of the exhibitors here →



## Mentoring booths

Booth	Exhibitor	
#MB1	CSL Behring	
#MB2	Bayer	
#MB3	Swissmedic	

### Mentoring booths

Hall 4.1

Explore the mentoring booths from Bayer, CSL Behring, and Swissmedic, offering personalized guidance to participants. Take the opportunity to gain insights from industry leaders and enhance your professional journey.

#### Mentoring booth 1 (MB1): CSL Behring

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.

#### Mentoring booth 2 (MB2): Bayer

Bayer is a global enterprise with core competencies in the life science fields of healthcare and agriculture. We design our products and services to help tackle some of the world's biggest challenges, and to serve the most essential human needs of health and nutrition. Let's collaborate to cure to bring innovation to patients!

#### Mentoring booth 3 (MB3): Swissmedic

From development to market surveillance Swissmedic is the Swiss authority for licensing and monitoring of therapeutic products. We ensure that the therapeutic products we approve are of faultless quality, effective and safe. Swissmedic is involved in the entire life cycle of a medicinal products because of its mandated areas of responsibility in the sectors of licensing and the authorization and monitoring of therapeutic products.

# Poster presentation

No.	Company	Hall 4.1
#1	4D Lifetec	
#2	Abologix	
#3	Adoram Therapeutics	
#4	AlphaMol Science	
#5	AlveoliX	
#6	Amphasys	
#7	Antion Biosciences	
#8	Atanis Biotech	
#9	Azafaros Switzerland	
#10	BigOmics Analytics	
#11	chAlron	
#12	Debiotech	
#13	Ectica Technologies	
#14	Edelweiss Connect	
#15	Embion Technologies	
#16	Eviden	
#17	FinalSpark	
#18	FluoSphera	
#19	HekeTiss	
#20	Incaptek	

No.	Company	Hall 4.1
#21	InkVivo Technologies	
#22	inSEIT	
#23	InSphero	
#24	IPS Biopharma	
#25	MedScienceSwiss	
#26	Mysthera Therapeutics	
#27	Nagi Bioscience	
#28	Novochizol	
#29	Onena Medicines	
#30	Ontrack Biomedical	
#31	Orion Biotechnology Switzerland	
#32	Oryl Photonics	
#33	PDC Therapeutics	
#34	Pilatus Biosciences	
#35	Quant Biomarkers	
#36	Risklick	
#37	Roumai Medical	
#38	Selmod	
#39	TissueLabs	



# Registered companies

(as of the 11 April 2024)

Member of the Swiss Biotech Association ●

Company	Country	
[iit] Business Intelligence	DE	
+ND Capital	CH	
>>venture>>	CH	
2 Bridge	BE	
2bind GmbH	DE	
3B Biotech Research	CH	●
3i Group plc	CH	
3PBIOPHARMACEUTICALS, S.L.U	ES	
3T Biosciences Europe GmbH	CH	●
4BIO Partners LLP	GB	
4D Lifetec AG	CH	
4TEEN4 Pharmaceuticals GmbH	DE	
7AlpsBio GmbH	CH	●
A&M Labor GmbH	DE	
A3P SUISSE	CH	
A4Bee	PL	
AAA Family Office	IL	
AAtec Medical GmbH	DE	
AB2 Bio Ltd	CH	●
Abbisko Therapeutics Co., Ltd.	CN	
AbbVie Deutschland GmbH Co. KG	DE	
abc biopply ag	CH	●
abcDNA GmbH	CH	●
Abenza	GB	
Abologix Sàrl	CH	●
AC Bioscience SA	CH	●
AC Immune SA	CH	●
ACCELERERA S.r.l.	IT	
Accelsiors AG	CH	
Acino International AG	CH	
ACM Biosciences AG	CH	●
acmaios GmbH	DE	
ACROBiosystems AG	CH	●
AD-MSAT biopharm SAS	FR	
Adaptly Biosystems Sarl	CH	
Adare Pharma Solutions	IT	
Addex Therapeutics Ltd	CH	●
Adienne Pharma & Biotech SA	CH	●
Aditum Bio	US	

Member of the Swiss Biotech Association ●

Company	Country	
ADMEDDICON - DMPK Consulting	DE	
Adnovate Clinical Development Strategies Ltd.	GB	
Adoram Therapeutics SA	CH	●
AdRegeneer AG	CH	
AdvanceCT	US	
Advanced Clinical	US	
Advanced Clinical Switzerland GmbH	CH	●
Advestra AG	CH	
Advesya AG	CH	●
Advitech Advisory and Technologies SA	CH	
AGC Biologics A/S	DK	
AGC Pharma Chemicals Europe, S.L.U.	ES	
AGEFI - Nouvelle Agence Économique et Financière	CH	
Agility Life Sciences Limited	GB	
Alcloud., Ltd.	KR	
AlMorphous Health	CH	
Air Liquide - BioKryo lyaly	IT	
Aldevron	US	
Alentis Therapeutics AG	CH	●
Alfasigma Schweiz AG	CH	
Alhena Consult	FR	
Alira Health AG	CH	●
Alira Health GmbH	DE	
Alira Health SLU	ES	
Alira Health Srl	IT	
AlivaMab Biologics, LLC	US	
Allegria Therapeutics AG	CH	●
Alloy Therapeutics	US	
Alltim GmbH	CH	
Almac Group	GB / DK	
Almasan AG	CH	
Almirall S.A.	ES	
Alpha Lyncis SA	CH	●
AlphaMol Science AG	CH	●
AlphaOnco Swiss SA	CH	●
Alpina Life Science Advisors	CH	
ALPX SAS	FR	
Altasciences	CA	●
AlveolIX AG	CH	●

## Member of the Swiss Biotech Association ●

Company	Country	
Amarna Therapeutics BV	NL	
Amazentis SA	CH	●
Amgen (Europe) GmbH	CH	
Aminoverse B.V.	NL	
Amo Life Science	KR	
AMOLIFSCIENCE	KR	
Ampersand Capital	NL	
Amphasys AG	CH	●
Amphilix AG	CH	●
Amporin Pharmaceuticals	CH	
AMR Action Fund	CH	
Amt für Wirtschaft und Arbeit, Abteilung Standortförderung	CH	
AMYRA Biotech AG	CH	●
AnaPath Services GmbH	CH	●
ANAPHARM EUROPE SLU	ES	
ANAQUANT	FR	
Anaveon AG	CH	●
anavo medical	CH	
Ancora.ai	CH	
ANDRE ROLAND SA	CH	
anteris Helvetia AG	CH	●
Antibody Analytics Ltd.	GB	
Antion Biosciences SA	CH	●
APC Ltd	IE	
Apeloa Europe GmbH	DE	
Aphaia Pharma AG	CH	●
APICES SOLUCIONES S.L.	ES	
APIM Therapeutics AS	NO	
Apollo Ventures Holding GmbH	DE	
Aptar Pharma	FR	
Aptar Stelmi SAS	FR	
Aragen Life Sciences Ltd	NL	
ARAYMONDLIFE	FR	
ARaymondLife SASU	FR	
Arcadis	CH	
Ardena Assen	NL	
Ardena Holding NV	BE	
ARENSIA Exploratory Medicine GmbH	DE	
Ariane Mansouri Consulting	DE	
Ariceum International AG	CH	●
Arphamid Therapeutics GmbH	CH	●
ArtBio GmbH	CH	●
Asahi Kasei Europe GmbH	DE	
Asaparia Glycomics S.L.	ES	
Asgard Cleanroom Solutions Ltd	IE	

## Member of the Swiss Biotech Association ●

Company	Country	
ASGENTO	DE	
ASOCIACIÓN BASQUE HEALTH CLUSTER	ES	
Asociación Española de BioEmpresas (AseBio)	ES	
Asparia Glycomics S.L.	ES	
Association of Biotechnological Companies BioForum	PL	
Astellas Pharma Europe	GB	
Astrum CRO S.L.	ES	
Atanis Biotech AG	CH	●
Athebio AG	CH	●
Athos KG	DE	
ATLANCHIM PHARMA	FR	
ATLANTIC BONE SCREEN	FR	
ATLyphe AG	CH	●
Atopia Therapeutics SA	CH	●
ATUM	US	
Augmented LLC	US	
Aukera Therapeutics GmbH	CH	●
Aurealis Therapeutics AG	CH	●
Auregen Biotherapeutics SA	CH	●
Aurigene Pharmaceutical Services Ltd.	IN	
Aurigon GmbH	DE	
Austrian Business Agency Österreichische Industriensiedlungs- und WirtschaftswerbungsgmbH	AT	
Avance Basel GmbH	CH	●
Avantor/ VWR International	DE	
Avinya Biotech	IN	
Avrion Therapeutics AG	CH	●
AWP Finanznachrichten	CH	
AXXAM SPA	IT	
Azafaros Switzerland AG	CH	●
B SQUARED Sarl	CH	●
B.PL AG - Biotech & Pharma Logistics	CH	
Baccinex SA	CH	●
Bachem AG	CH	●
Bacthera	CH	
Baden-Württemberg International GmbH	DE	
BakerHicks AG	CH	●
Balgrist Campus AG	CH	
Baliopharm AG	CH	●
Bambooster	CH	
bamconn GmbH	DE	
BAP Pharma Ltd	GB	
Bär & Karrer AG	CH	
Basel Area Business & Innovation	CH	
BaseLaunch	CH	
Basic Pharma	NL	

Member of the Swiss Biotech Association ●

Company	Country	
Basilea Pharmaceutica Ltd.	CH	●
Bavarian Nordic Berna GmbH	CH	●
Baxalta Innovations GmbH	AT	
Bayer AG	DE	
Bayer Schweiz AG	CH	
BBD BioPhenix S.L.U.	ES	
BBIT-Therapeutics	PT	
BD as a Service	CH	
BEAT Therapeutics	PT	
Beech Biotech SA	CH	
BelGene	CH	
Belgian Volition SRL	BE	
Berlin Partner für Wirtschaft und Technologie GmbH	DE	
Bern Economic Development Agency	CH	
BERNINA BioInvest AG	CH	●
BFLOW, S.L.	ES	
BigOmics Analytics SA	CH	●
BIO Deutschland e. V.	DE	
Bio-Techne AG	CH	●
Bio-Technopark Schlieren-Zürich	CH	●
Bio2Business Ltd	GB	
BIO4 d.o.o.	RS	
BioAglytix	US / DE	
BioAlps Association	CH	
BioAudix AG	CH	
BIOCOM AG	DE	
BioConcept AG	CH	●
BioConnection BV	NL	
BioDecision Analytics Ltda	BR	
BioDuro LLC	US	
Bioengineering AG	CH	●
BioFI AG	CH	
BIOGA – Clúster Tecnológico Empresarial das Ciências da Vida	ES	
BioGeneration III Services BV	NL	
BioGenes GmbH	DE	
Bioingenium	ES	
BioIVT	US	
Biokinetica S.A.	PL	
BioKryo GmbH	DE	
BioKryo SA	FR	
BioLAGO e.V.	DE	
BioLingus	CH	●
BioLizard	BE	
Biolizard NV	BE	
BioM Biotech Cluster Development GmbH	DE	

Member of the Swiss Biotech Association ●

Company	Country	
BioMedPartners AG	CH	●
biomindz Standortentwicklungsgesellschaft Mainz mbH	DE	
BioNetLink by GlobalBiotec	MX	
Biopharma Process Systems	GB	
Biopôle SA	CH	●
BioReperia AB	SE	
BioRN Cluster Management GmbH	DE	
biosaxony Management GmbH	DE	
BioSolveIT GmbH	DE	
Biosynth Carboxynth	CH	●
biotactical B.V.	NL	
BioTalent Ltd	GB	
Biotech Booster	NL	
Biotechnet Switzerland	CH	
BIOTEM	FR	
Bioton S.A.	PL	
Biotrial International Ltd	GB	
BIOTRONIK	CH	
BIOTYPE GmbH	DE	
BioVation RLP	DE	
BIOVECTRA	CA	
BioVersys AG	CH	●
BioXpress Therapeutics SA	CH	●
bit.bio	GB	
BlackRock Asset Management (Switzerland) Ltd	CH	
bisc - bihlmann life science communication	CH	●
Blueprint Genetics Oy	FI	
BMD Life Sciences GmbH	DE	
Boehler Life Science Advice	CH	●
Boehringer Ingelheim Venture Fund GmbH	DE	
Bonetti & Partner GmbH	CH	●
Bora Biologics Co., Ltd.	TW	
Botschaft des Königreichs der Niederlande	CH	
Bovard AG	CH	
BPG-Partners	CH	
Brazilian Pharmaceutical Innovation Network - RBIF	BR	
Bright Peak Therapeutics AG	CH	●
Broadview Ventures	US	
Budenheim	DE	
Bundesamt für Gesundheit	CH	
Business Oregon	US	
CAI Suisse SA	CH	
Calico Biosystems	CH	
Calida Therapeutics SAS	FR	
Cambrex Corporation	US	

Member of the Swiss Biotech Association ●

Company	Country	
Cancer Research and Biotechnology AG	CH	●
CarVirex AG	CH	●
Carbogen Amcis AG	CH	●
Careforce Switzerland AG	CH	
Carina Schey	CH	
Catalent Pharma Solutions GmbH	CH	●
Catalonia Trade & Investment	DE	
Catalyze Switzerland GmbH	CH	●
Catenion GmbH	DE	
Catherinn BV	NL	
CDR-Life AG	CH	●
CeGaT GmbH	DE	
Ceidos SA	CH	●
Celerion Switzerland AG	CH	●
Cell-Easy	FR	
Cellerys AG	CH	
Cellestia Biotech AG	CH	●
CellProthera SAS	FR	
Cellula Therapeutics SA	CH	●
cellvie AG	CH	●
CellX Biosolutions, Stocker lab	CH	
Celonic AG	CH	●
Cencora PharmaLex	FR	
Centella AI Therapeutics	IN	
Centella Scientific Pvt.Ltd	IN	
Center for Integrative Genomics, University of Lausanne	CH	
Centerview Partners	GB	
Ceppi Consulting	CH	
Cerbios-Pharma SA	CH	●
Cetacea Consulting GmbH	CH	●
Cfm Oskar Tropitzsch GmbH	DE	
CG Chemikalien GmbH & Co. KG	DE	
chAlron SA	CH	●
Changchun GeneScience Pharmaceutical Co., Ltd.	CN	
Charles River	FR	
Charmwood Discovery a trading name of Charmwood Molecular Ltd	GB	
Chelonia SA	CH	●
ChemCon GmbH	DE	
Chemengineering Switzerland AG	CH	●
Chemische Fabrik Budenheim KG	DE	
Chemische Fabrik Budenheim KG, Rheinstraße 27, 55257 Budenheim/ Germany	DE	
CHIESI FARMACEUTICI SPA	IT	
Children's Tumor Foundation Europe	BE	
Chinsiders GmbH	CH	●
Choose New Jersey	DE	

Member of the Swiss Biotech Association ●

Company	Country	
CIC bioGUNE	ES	
Cilag AG	CH	
Cilatus Biopharma Consulting AG	CH	●
Ciloa SAS	FR	
Cimeio Therapeutics AG	CH	●
CIS Biopharma AG	CH	●
Citeline	GB	●
CK Associates Ltd	US	
CLADE GmbH	DE	
CLEAN BIOLOGICS	FR	
Clean Cells	FR	
Cleracs Consulting LLC	US	
Clinexel Life Sciences Pvt Ltd	IN	
Clinical Research Services Turku-CRST Oy	FI	
Clinical Services International	GB	
Clinigen Group - Clinical Supplies Management	GB / BE / DE	
Clinmark	PL	
ClinOps Advisory Turner GmbH	CH	●
CNRS	FR	
CNRS UMR 8104	FR	
Collaborative Drug Discovery	US	
COMAC MEDICAL	BG	
Commissioning Agents International	CH	
CompagOs AG	CH	
Compartis	CH	
Complyomics Sarl	CH	●
Concept Life Sciences	GB	
Consultant	CH	
Copyright Clearance Center	GB	
Corden Pharma International Switzerland LLC	DE	
Cordenpharma	CH	
Corning BV	NL	
Cortex Discovery GmbH	DE	
Coulter Partners	CH	●
CRB Group GmbH	CH	●
CREAPHARM BIO&PHARMA	FR	
Credit Suisse	CH	
Crelux GmbH	DE	
CROSS Research SA - CROSS Alliance®	CH	●
Crown Bioscience Inc.	US	
CSEM	CH	●
CSL Behring	CH	●
CSL Seqirus	GB	
CTC Resourcing Solutions AG	CH	●
CTI - Clinical Trial & Consulting GmbH	DE	

Member of the Swiss Biotech Association ●

Company	Country	
CUBE LABS SPA	IT	
Cubic K Co., Ltd.	KR	
Culture Collection of Switzerland AG	CH	●
Curare Consulting BV	NL	
Curare Swiss AG	CH	●
Cureline AG	CH	●
Cureteq AG	GB	
Curia Global Inc	GB	
Curie.Bio	US	●
CUTISS AG	CH	●
Cytek Biosciences BV.	NL	
Cytel Inc.	GB	
CYTES BIOTECHNOLOGIES S.L.	ES	
Cytiva Europe GmbH	CH	●
CZ Vaccines	ES	
DACH-Pharmaconsulting	DE	
Daiichi Sankyo Europe GmbH	US	
Dalriada Drug Discovery	CA	
DAMIAN Pharma	CH	
Dao Tun GmbH	CH	●
Datasite	CH	
DCZ Executive Search GmbH	DE	
De Bord International	CH	
Debiopharm Innovation Fund	CH	
Debiopharm International SA	CH	●
Debiotech SA	CH	
Defossilisation Development Fund	CH	
Delin Ventures	CH	
Department of Economic Affairs Canton of Zug	CH	
Department of Innovative Technologies - University of Applied Sciences and Arts of Southern Switzerland	CH	
Dermaliq Therapeutics GmbH	DE	
Deutsches Zentrum für Neurodegenerative Erkrankungen	DE	
Dextronix, Inc.	US	
DHL Express (Switzerland) Ltd.	CH	
DIAMANTE Healthcare Consulting Sagl	CH	
DiaSorin SA/NV, Dutch Branch	NL	
DICE CRO	BE	
DICella	PL	
DIDEOLU MULTI CONCEPT LIMITED	NG	
dieter mueller- medical device & pharma consulting gmbh	DE	
digitalswitzerland	CH	
DINAMIQS	FR	
Dinaqor AG	CH	●
Direction générale du développement économique	CH	
Discovery Life Sciences	US	

Member of the Swiss Biotech Association ●

Company	Country	
DIVERSA TECHNOLOGIES SL	ES	
DLA PIPER	FR	
DLRC Ltd	GB	
Dottikon Exclusive Synthesis AG	CH	
Dr. Helene Chery-Hernandez	DE	
Droia Ventures	BE	
E. Blum & Co. AG	CH	
EA Pharma Co., Ltd.	JP	
EBD Group GmbH	DE	
Ebury Partners Switzerland AG	CH	
ECCLEION	IT	
ecoplus. Niederösterreichs Wirtschaftsagentur GmbH	AT	
ECPM, University of Basel	CH	
Edelris	FR	
Edelweiss Connect GmbH	CH	●
EdgeOne Venture Partners	US	
EffRx Pharmaceuticals SA	CH	●
Egon Zehnder International	CH	
EIRNA Bio Ltd	IE	
Eisai Pharma AG	CH	
Elda Kutrolli (WUR)	SE	
Eli Lilly	CH	●
Eli Lilly and Company	US / GB	
Elix International SA	CH	
Elilab AG	CH	
Elsevier B.V.	NL	
Elthera AG	CH	●
Embassy of Canada	CH	
Embassy of Switzerland in the UK	GB	
Embassy of the Kingdom of the Netherlands	CH	
Enable Biotech AG	CH	●
Enamine Germany GmbH	DE	
Enantia, SL	ES	
Encelta AG	CH	
Endogena Therapeutics AG	CH	●
Engimmune Therapeutics AG	CH	
EPFL university	CH	
EPFL, Technology Transfer Office	CH	
EPIC Suisse AG	CH	●
Epics Therapeutics SA	BE	
Epistem Limited	GB	
Epiterna	CH	
EPITERNA SA	CH	
EQT Life Sciences	DE	
EraCal Therapeutics Ltd	CH	●

## Member of the Swiss Biotech Association ●

Company	Country	
ERBC France	FR	
Ergomed GmbH	DE	
Ergomed Virtuoso Sàrl	CH	
Ernst & Young AG	CH	●
EsoCap AG	CH	
EspeRare Fondation	CH	●
ETH Zurich	CH	
EuremAb Srl	IT	
Euresearch	CH	
Eurofins Amatsigroup SAS - CFR175	FR	
Eurofins BioPharma Product Testing Switzerland AG	CH	●
Eurofins Central Laboratory B.V.	NL	
Eurofins Discovery	FR	
Eurofins Genomics	DE	●
Eurofins Selcia Ltd	GB	
EUROMED PHARMA France	FR	
Euromed Pharma Srl A socio unico	IT	
European Biosolutions Coalition	DK	
European Centre for Clinical Research Training	BE	
European Pharmaceutical Students' Association	BE	
EVERSANA Life Science Service LLC	US / GB	
Eversheds	US	
Eviden AG	CH	●
Eviive	CH	
Evitria AG	CH	●
EvlaBio AG	CH	●
Evolution Europe S.L.	ES	
Evotec SE	DE	
EWOPHARMA AG	CH	
ExcellGene SA	CH	●
Excelya	FR	
ExecMind	PL	
Executegy GmbH	CH	
Experimental Pharmacology & Oncology Berlin-Buch GmbH	DE	
Exscientia	GB	
Exyte Central Europe GmbH	CH	
Eyam Vaccines and Immunotherapeutics Ltd.	CA	
F. Hoffmann-La Roche AG	CH	●
FARAFINA INVESTMENT GROUP INC.	GH	
FatiAbGen International GmbH	CH	●
FB Global Regulatory Consulting and Coaching	CH	●
Ferring Pharmaceuticals	DK / CH	
FGK Clinical Research GmbH	DE	
FHNW	CH	
FimmCyte AG	CH	●

## Member of the Swiss Biotech Association ●

Company	Country	
FinalSpark Sàrl	CH	●
Finanz und Wirtschaft / Tamedia	CH	
FingerPost Consulting Ltd	GB	
Finnish Biobanks - FINBB	FI	
Fischer PreclinTox Consulting	CH	●
Flanders Investment & Trade	CH	
Floratek Pharma SA	CH	●
FLOTOR MEDIA SOLUTIONS SL	ES	
Flow Technology Ltd	IE	
FluoSphera SA	CH	●
Fondation Campus Biotech Geneva	CH	
Fongit	CH	
Forbion - FCPM III Services BV	NL	
Foretell My Health	KR	
Fortrea GmbH	DE	
Fortrea Switzerland AG	CH	●
Forty51 Advisors AG	CH	●
FoRx Therapeutics AG	CH	●
Fosun Pharmaceutical AG	CH	
Francesca Belli Novak - BelliLS	IT	
FTherapeutics	ES	
Fundacion MEDINA	ES	
Future Fields Cellular Agriculture & Research Ltd.	CA	
FyonBio GmbH	DE	
GalChimia, S.A.	ES	
Gaiser SA	CH	●
Ganda Business Solutions	CH	●
GARDP Foundation	CH	
Gases, Research, Innovation & Technology S.L. (GRIT)	ES	
GATE2BRAIN S.L.	ES	
GBiotech Sàrl	CH	●
GCELL CULTIVO 3D	BR	
Gearbox Biosciences	EE	
Gellycycle Co., Ltd.	JP	
GemPharmatech Co., Ltd.	CN	
Gemseki Inc.	JP	
Genesis Healthcare Co.	JP	
Genesupport SA	CH	●
GeNeuro SA	CH	●
Genewity B.V.	NL	
Genius Search GmbH & Co. KG	DE	
GenomeScan	NL	
GenSearch Switzerland GmbH	CH	●
Germany Trade and Invest GmbH	DE	
Gimv NV	BE	

Member of the Swiss Biotech Association ●

Company	Country	
GIO Therapeutics AG	CH	●
GKM Ges. für Therapieforschung mbH	DE	
Glatt GmbH	DE	
Glengarra	CH	
GliaPharm SA	CH	●
GlycoEra AG	CH	●
Glycomscan B.V.	NL	
Gnubiotics Sciences Sàrl	CH	●
Gouya Insights GmbH und Co KG	AT	
Grand E-nov+	FR	
Grand River Aseptic Manufacturing	US	
Granite Bio AG	CH	●
GRASO ZENON SOBIECKI	PL	
Greater Geneva Bern area	CH	
Greaves Brewster LLP	GB	
GT Gain Therapeutics SA	CH	●
GTP Bioways	FR	●
GxpManager	FR	●
H & B Real Estate AG	CH	
HALIX B.V.	NL	
Hamilton Bonaduz AG	CH	
Handelskammer beider Basel	CH	
Hangzhou HealSun Biopharm Co., Ltd.	CN	
Harmonic Discovery Inc	US	
Haya Therapeutics SA	CH	●
HBM Partners AG	CH	●
HdB-Law	CH	
headcount AG	CH	●
Healiva SA	CH	●
Health Advances GmbH	CH	●
Health-Holland	NL	
HealthiBuddy Co., Ltd.	KR	
Heap Research Bv	NL	
HekeTiss SA	CH	●
Hellenic Biocluster (HBIO)	GR	
Helsinn Healthcare SA	CH	●
HEMEX AG	CH	●
HemostOD SA	CH	●
Hermay Labs Corporation	CA	
HES-SO Valais Wallis	CH	
HGF GmbH	CH	●
Hirata Corporation	JP	
Hire Collider GmbH	CH	
Hobson Prior Europe GmbH	CH	
Hoffmann & Partner AG	CH	●

Member of the Swiss Biotech Association ●

Company	Country	
Homburger AG	CH	●
Honeywell Healthcare solutions GmbH	DE	
Honour Lab Limited	IN	
Hovione FarmaCiencia SA	PT	
HTCR-Services GmbH	DE	
HUB Brussels	CH	
Humabs BioMed AG	CH	●
Human Genomics	CH	
HungaroTrial	HU	
IBI - Istituto Biochimico Italiano Giovanni Lorenzini S.p.a.	IT	
IBR Inc. Institute for Biopharmaceutical Research	CH	●
Ichnos Sciences SA	CH	●
ICON	IE	
ICON Clinical Research (Switzerland) GmbH	CH	●
Icosagen Cell Factory OÜ	EE	
iCure SA	CH	●
IDDI SA	BE	
Idemitsu Research and Business Development Europe AG	CH	
IDEXX BioAnalytics	US	
IKA-Werke GmbH & Co. KG	DE	
ILIAS Biologics, Inc.	KR	
ImeBIO	FR	
IMG Investitions- und Marketinggesellschaft Sachsen-Anhalt	DE	
Immunophotonics / IPS Biopharma AG	CH	●
ImmunOs Therapeutics AG	CH	●
ImmunSkills SA	CH	●
IMPLANZ	CH	
Inbeoo	GB	
Incaptex Sàrl	CH	●
InCephalo AG	CH	●
Incyte Biosciences International Sàrl	CH	●
Independent Participant	CH	
Infinity Communications Sarl	CH	●
InflaRx GmbH	DE	
infoteam Software AG	CH	
Inizio Healthcare Ltd	GB	
Inkocell Therapeutics	CH	
InkVivo Technologies AG	CH	●
InnoGI Technologies	NL	
InnoMedica	CH	
Innosuisse	CH	
Innovative Technologies in Biological Systems, SL	ES	
Innovaud	CH	
INOFEA AG	CH	●
Inovatie Serviços em Saúde	BR	



## Member of the Swiss Biotech Association ●

Company	Country	
INOVATION	FR	
InSCREENeX GmbH	DE	
inSEIT Biotech	CH	●
InsideReg Sarl	CH	●
Insilico Medicine Hong Kong Limited	HK	
Institute of Oncology Research	CH	
Istituto Biochimico Italiano G. Lorenzini S.p.A.	IT	
INSTYTUT BIOLOGII DO WIADCZALNEJ IM. MARCELEGO NENCKIEGO POLSKIEJ AKADEMII NAUK	PL	
IntelDrug Consulting Pospisil	CH	●
InterAx Biotech AG	CH	●
Intrajel Therapeutics	IL	
Intralink Group Limited	GB	
INTRIALS PESQUISA CLÍNICA LTDA	BR	
Invest in LODZ	PL	
InvestHK	DE	
IPS-Integrated Project Services GmbH	CH	●
IQone Healthcare Switzerland SA	CH	●
IQVIA AG	FR / CH	●
Iris Biotech GmbH	DE	
Ironwood Pharmaceutical	CH	●
Italfarmaco S.p.A	ES	
ITK Engineering GmbH	DE	
J. Lamarck Asset Management SA	CH	●
Jackson Laboratory	US	
Jacobs	DK	
Jacobs Ireland	IE	
Jacobs Switzerland GmbH	CH	●
Jagotec AG - Vectura Fertin Pharma	CH	●
Jeito Capital	FR	
JFG Life Sciences Stiftung der Universität Basel	CH	●
Johnson & Johnson Innovation Ltd	UK	
JPMorgan	GB	
Jubilant Biosys Limited	IN	
Justin Stindt Consulting AG	CH	
Kaneka Eurogentec S.A.	BE	
Kapadi	PL	
KBI Biopharma SA	CH	●
KCAS Bio	US / FR	
Kellerhals Carrard	CH	●
Kerna Ventures	GB	
kineo finance AG	CH	
Kisco Sarl	CH	●
KISSEI AMERICA, INC.	US	
KLIFO A/S	DK	
KLIFO GmbH	DE	

## Member of the Swiss Biotech Association ●

Company	Country	
Koralis Corporate	NL	
KornFerry	CH	
KOTRA	CH	
Kowa Pharmaceuticals Europe AG	CH	
KPMG AG	CH	●
KreaMedica Inc.	CA	
KriSan Biotech Co., Ltd.	TW	
Kurma Partners	FR	
KVALITO AG	CH	●
KVWL	DE	
KYLYS AESTHETICS SA	CH	
KyooBe Tech GmbH	DE	
Kyorin Pharmaceutical Co., Ltd.	JP	
LabConnect Europe	NL	
Labcorp Central Laboratory Services Sarl	CH	●
Labcorp SARL	FR	
LabForce AG	CH	●
LABORATOIRES GRIMBERG	FR	
LabWare France	FR	
LabWare Switzerland	CH	
Laevoroc Oncology AG	CH	●
LAGOSTA SA	CH	●
Lambda-X	BE	
Latvian Institute of Organic Synthesis	LV	
Laviana Pharma Co., Ltd.	CN	
LayerBio, Inc.	US	
Le Temps	CH	
Leads To Development	FR	
leadXpro AG	CH	●
Leanbio S.L.	ES	
Leiden University Medical Center	NL	
Leman Biotech Lausanne SA	CH	●
Lenz & Staehlin	CH	
Leukocare AG	DE	
LGD France	FR	
Libbs Farmacéutica	BR	
LIBERA BIO, S.L.	ES	
Life Science Sachsen-Anhalt e.V.	DE	
Life Science Zurich Young Scientist Network	CH	
Life Sciences Switzerland - LS2	CH	
LimmaTech Biologics AG	CH	●
Limula SA	CH	●
Linical Europe GmbH	DE	
Lock and Key Biosciences GmbH	CH	
Loriza AG	CH	●

Member of the Swiss Biotech Association ●

Company	Country	
LoopLab Bio GmbH	AT	
Loyal VC	CH	
LS Instruments AG	CH	●
LubioScience GmbH	CH	●
Lucerna Chem AG	CH	●
Luminance Health GmbH	CH	●
Lumis International GmbH	DE	
LUPIN	CH	
Luto Research Ltd	GB	
Lygature	NL	
Lymphome.ch Patientennetz Schweiz	CH	
LYO-X AG	CH	●
M2M Bio Limited	GB	
MabDesign	FR	
MabTree Biologics AG	CH	●
Mabylon AG	CH	●
Magnitude Biosciences	GB	
Maiwald GmbH	DE	
Malcisbio AG	CH	
MAPREG	FR	
maruho Deutschland GmbH	DE	
MatTek	US	
Maven Health GmbH	CH	
Maxia Strategies GmbH	CH	●
McArthur and Associates GmbH	CH	●
MCE Carrel Avocats SA	CH	
Med Discovery SA	CH	●
Medace BV	NL	
Mederis	CH	●
MEDExpansion Sàrl	CH	●
Median Technologies	FR	
Medical Inventi	PL	
Medicilon Inc.	CN	
Medico Digital Solutions Ltd	GB	
Medicon Valley Alliance	DK	
MediTox s.r.o.	CZ	
Medpace, Inc.	US	
Medperion GmbH	DE	
MedScienceSwiss AG	CH	●
Medvisis Switzerland AG	CH	●
MedXCell SA	CH	●
Memo Therapeutics AG	CH	●
Menarini Biotech SRL	IT	●
Merck & Cie	CH	
Merck Healthcare KGaA; Germany	DE	

Member of the Swiss Biotech Association ●

Company	Country	
Mestastop Solutions Private Limited	IN	
metaLead Therapeutics AG	CH	
Metronomia Clinical Research GmbH	DE	
Mettler Toledo	CH	
MF Life Sciences GxP Consulting GmbH	CH	●
Microcity SA	CH	
Microsynth AG	CH	●
Midas Pharma GmbH	DE	
Milian SA Dutscher Group	CH	
Miltenyi Biotec B.V. & Co. KG	CH	
MIMABS	FR	
Ministry of Economic Affairs, Transport, Agriculture and Viticulture Rhineland-Palatinate	DE	
Mirum Pharmaceuticals	CH	
MLM Medical Labs GmbH	DE	
MOD1 AG	CH	●
Molecular Partners AG	CH	●
MolGenie	DE	
Monte Rosa Therapeutics AG	CH	●
Moonlight AI Sàrl	CH	●
Morimatsu Italy	IT	
Mosanna Therapeutics AG	CH	●
MRGN Advisors Sàrl	CH	●
MSD	GB	
MUVON Therapeutics AG	CH	●
MV BioTherapeutics SA	CH	●
Mydata-TRUST	BE	
Myomar Molecular	CA	
Myonex GmbH	DE	
N&Sz StudyMaster Ltd	HU	
Nad Consulting (for GRIP-pharma)	CH	
Nagi Bioscience SA	CH	●
NAOBIOS	FR	
Nathalie Jenni Consulting GmbH	CH	●
Navignostics AG	CH	●
NBE-Therapeutics AG	CH	●
NCMA Consulting GmbH	CH	●
Nebion AG (an Immunai company)	CH	
Nederlandse Organisatie voor toegepast natuurwetenschappelijk onderzoek TNO	NL	
NegotiumBio Schweiz GmbH	CH	●
NeoCarbons sa	CH	
NerPharMa Srl	IT	
Nerviano Medical Sciences srl	IT	
Nested Knowledge	US	
NETDA	CN	
Netherlands Enterprise Agency	NL	

Member of the Swiss Biotech Association ●

Company	Country	
Netherlands Innovation Network	DE	
NETRIS Pharma	CH	
Neuland Laboratories Limited	CH	
Neurimmune AG	CH	●
New England Biolabs GmbH	DE	
NewBiologix SA	CH	●
Nexco Analytics Sarl	CH	●
NeXendia	CH	
NexMR GmbH	CH	●
NextCell Pharma AB	SE	
Nextech Invest	CH	
Nextherapy	CH	
Nimble Science Ltd	CA	
NOF CORPORATION	JP	
Northway Biotech	LT	
Nouscom AG	CH	●
NovAIIX	FR	
Novaremed AG	CH	●
Novartis Foundation	CH	
Novartis Pharma AG	CH	●
Novartis Pharma B.V.	NL	
Novassay SA	CH	
Novigenix Sa	CH	●
Novo Nordisk Health Care AG	CH	
Novochizol SA	CH	●
NOVOGENE GMBH	DE	
Novozymes AG	CH	
NTrans Technologies	NL	
Nubilaria srl	IT	
Nucleate	US	
Numab Therapeutics AG	CH	●
NXGEN Medical Services AG	CH	
NXI Therapeutics AG	CH	●
OCCIDENT Group AG	CH	●
OCT Clinical GmbH	DE	
Oculus Operations Sarl	CH	●
Oficina Económica y Comercial de España en Suiza	CH	
Olgram SA	CH	●
Olon S. p. A.	IT	
OM Pharma	CH	●
OMNI Life Science GmbH	CH	●
OmnilinX Therapeutics	CH	●
Oncode Accelerator Foundation	NL	
Oncodesign Services	FR	●
Oncotec Pharma Produktion GmbH	DE	

Member of the Swiss Biotech Association ●

Company	Country	
Onena Medicines AG	CH	●
ONIRIA THERAPEUTICS, S.L.	ES	
Only Orphans Cote LLC	US	
Ono Pharmaceutical	GB	
Ontario Trade and Investment Office, Consulate of Canada	DE	
Ortrack Biomedical AG	CH	●
Onward Therapeutics SA	CH	●
OPIS srl	IT	
OPTIMA pharma GmbH	DE	
Optimapharm	HR	
Oractive Swiss AG	CH	●
Oregon Bioscience Association	US	
Oregon Business Development Department	US	
Organon International GmbH	CH	
Orio Therapeutics SA	CH	●
Orion Biotechnology Switzerland	CH	●
Orphamed ilaç ve Eczacı Anonim İrketi	TR	
Oryl Photonics SA	CH	●
Oryzon Genomics, S.A.	ES	
Oswaldo Cruz Foundation I Fiocruz	BR	
Otsuka Pharmaceutical Europe	GB	
Otten Life Sciences Consulting Sarl	CH	●
Oxford Global Resources	IE	
P4ML Ltd	IE	
Panda International	NL	
PAREXEL International (CH) AG	CH	●
Parithera SA	CH	●
Partex NV	DE	
Patheon, part of ThermoFisher Scientific	FR	
PathoQuest	FR	
Paul Scherrer Institute	CH	
PCI Pharma Services	US	
PDC Therapeutics SA	CH	●
Peptide	KR	
Peptone Switzerland AG	CH	●
PerioTrap Pharmaceuticals GmbH	DE	
Perseo Pharma AG	CH	●
Persistent Systems	IN	
Pestalozzi Attorneys at Law Ltd	CH	
Pfizer CentreOne	DE	
Pharma Quality Europe Srl	IT	
Pharma-Consulting ENABLE GmbH	CH	●
PharmaBiome AG	CH	●
PharmaBoardroom Limited	GB	
Pharmadule Morimatsu AB	IT	

Member of the Swiss Biotech Association ●

Company	Country	
Pharmafoxx Therapeutics	CH	
PharmaKorell GmbH	CH	●
Pharmaron Ltd	GB	
PHARMASSIST LTD	GR	
PharmEnable Therapeutics Limited	GB	
Phialogics AG	CH	
Phoenix CR	AE	
PIERRE FABRE SA	FR	
Piramal Pharma Solutions	US	
PlasmidFactory GmbH	DE	
plusbiome AG	CH	●
PLX Healthcare Services (Switzerland) AG	CH	●
Pohang City	KR	
Polish Investment&Trade Agency	PL	
PolyAn GmbH	DE	
PolyAnalytik Inc.	CA	
PolyPeptide Group AG	CH	●
PolyPeptide Laboratories France S.A.S	FR	
Polysciences Europe GmbH	DE	
Populus Bio Sarl	CH	●
Porton Pharmaceutical Chemicals GmbH	CH	●
Portrai Inc.	KR	
Pracipio Ltd	GB	
Praed Pharmaceuticals Ltd	CH	●
Precision NanoSystems ULC. (part of Cytiva)	CA	
PreComb Therapeutics AG	CH	●
Premier Research	IT	
Prescience Insilico Private Limited	IN	
Prestige Biologics Co., Ltd.	KR	
Priavoid GmbH	DE	
PricewaterhouseCoopers AG	CH	
Priosh PharmaChem AG	CH	
Probatech Ltd	GB	
ProBioGen AG	DE	
Promega AG	CH	●
ProtaGene CGT GmbH	DE	
ProtaGene GmbH	DE	
PROTEIN ALTERNATIVES SL	ES	
Proteintech Europe	GB	
PROTEOGENIX SAS	FR	
Proteros biostructures GmbH	DE	
Provectis Healthcare AG	CH	●
Prüfer & Partner mbB	DE	
PSI CRO AG	CH	●
Public enterprise Invest Lithuania	LT	

Member of the Swiss Biotech Association ●

Company	Country	
Pureos Bioventures	CH	●
Putnam	GB	
PwC Zurich	CH	
Q&C Services	CA	
Qanatpharma AG	CH	●
QBDC GmbH	CH	●
QIAGEN GmbH	DE	
Qiao Advisors GmbH	CH	●
QPS Netherlands BV	NL	
Quality Assistance	BE	
Quant Biomarkers AG	CH	●
Quay Pharmaceuticals Ltd	GB	
Quotient Sciences	GB	
RadaHaim Co., Ltd.	KR	
RADAR RP Sarl	CH	●
RAMBAM AG	CH	●
RAV Basel-Stadt	CH	
RC Tritec AG	CH	
RD-BIOTECH	FR	
RDP Pharma AG	CH	●
Receptor.ai Ltd.	GB	
Recipharm / RecBioPharm	US	
Recipharm AG	CH	
Reconnect Labs AG	CH	●
REGenerative MEDicine Crossing Borders (RegMed XB)	NL	
Rejuveron Life Sciences AG	CH	●
Renaldee AG	CH	●
Rentschler Biopharma SE	DE	
Représentation économique et commerciale de la Wallonie - Mission permanente Belge auprès de l'ONU	CH	
REPROCELL Europe Ltd.	GB	
Resea Biotec GmbH	CH	●
Resolian	GB	
RespAct GmbH	CH	●
Rewire AI	US	
Rheinessen Chamber of Commerce and Industry	DE	
Rhizen Pharmaceuticals AG	CH	●
RIBOPRO B.V.	NL	
Risklick AG	CH	●
ROCC GmbH (Rachel Ougier Consulting & Canvas)	CH	
Roche Diagnostics	CH	
ROCHE POLSKA Sp. z o.o.	PL	
Roivant Sciences GmbH	CH	
ROKIT HEALTHCARE Inc.	KR	
Roumai Medical (Switzerland) SA	CH	●
Sachs Associates Switzerland AG	CH	

Member of the Swiss Biotech Association ●

Company	Country	
Sai Life Sciences Ltd	GB / DE	●
SAKK	CH	●
Salesforce Sarl	CH	
Salvina Therapeutics AG	CH	●
SanaClis s.r.o.	SK	
Sanquin Health Solutions	NL	
Santen SA	CH	
Santhera Pharmaceuticals (Switzerland) AG	CH	●
Sartorius Stedim Biotech GmbH	DE	
Sartorius Stedim Switzerland AG	CH	●
Saxony Trade & Invest	DE	
Sbg Lifesciences/RHA Comms	CH	
Scandion Oncology A/S	DK	
Scendea Ltd.	GB	
SCG Siam Cement Group	TH	●
Science. People. Business.	CH	
scienceindustries	CH	
Sciential B.V.	NL	
Scinus cell expansion Netherlands BV	NL	
Scrip	GB	
Seagen International GmbH	CH	●
Securecell AG	CH	●
SEED Biosciences SA	CH	●
Sefunda AG	CH	●
Selmod GmbH	CH	●
Selvita Ltd	HR	
Selvita S.A.	PL	
Senbiosys	CH	
SENISCA Ltd	GB	
SENJU Pharmaceutical Co., Ltd	JP	
Senn Development AG	CH	
Service de l'Économie de Neuchâtel	CH	
SFL Pharma GmbH	CH	●
SFL Regulatory Affairs & Scientific Communication GmbH	CH	
SGInnovate	SG	
SGS	BE	
SGS Analytics Germany GmbH	DE	
SGS Analytics Switzerland AG	CH	●
SGS France	FR	
SGS Life Sciences Geneva	CH	●
SGS SA	CH	
SGS Vitrology Ltd	GB	
SH Medicilon Inc	CN	
Shanghai Medicilon Inc.	CN	
Shape Biopharmaceuticals GmbH	CH	

Member of the Swiss Biotech Association ●

Company	Country	
SHILPA MEDICARE LIMITED	IN	
SIB Swiss Institute of Bioinformatics	CH	
Sidrapex Pte Ltd	CH	
Sie Badawcza ŁUKASIEWICZ - Łódzki Instytut Technologiczny	PL	
Sigeon IP	PL	
Simbec-Orion	GB	
Sincere Pharmaceutical Group	CN	
Sindicato da Industria de Produtos Farmaceuticos - Sindusfarma	BR	
Sindusfarma	BR	
Sinfonie LSM GmbH	DE	
Singapore Innovate Pte Ltd	SG	
Sino Biological Europe GmbH	DE	
sitem-insel AG	CH	
SIX Swiss Exchange	CH	
SK PHARMTECO	FR	
SKM-IP Schmid Krauß Kuttenkeuler Malescha Schieler Patentanwälte PartGmbH	DE	
Skyvor Medical AG	CH	
Smile Incubator	SE	
Sodha Pharma Consulting GmbH	CH	
Solvias AG	CH	●
Somagenetix AG	CH	●
SOPHIA GENETICS	CH	●
Sotio Biotech AG	CH	●
SP Groups SA	CH	●
Specific Pig SI (specipig)	ES	
Spectralys Biotech SRL	BE	
Springer Nature Ltd	US / GB	●
STA Strategic Transactions Advisory AG	CH	
STALICLA SA	CH	●
Stämm Vegh SA	CH	●
Standortförderung Basel-Stadt	CH	
Startupticker	CH	
State of Valais - Economic Promotion Valais	CH	
Stem Cell Research and Regenerative Medicine Platform (SCRM), University of Bern	CH	
STEMCELL Technologies	CH	
Sterling Pharma Solutions	GB	
Stevanato Group SpA	IT	
Stolmár & Partner	CH / DE	
Stromal Therapeutics AG	CH	●
succelebrate-ag	CH	
Suisse Technology Partners	CH	
Sunstone Life Science Ventures	DK	
Supercomputing Systems AG	CH	
Superlab Suisse AG	CH	●
Supply Chain Operations SA	CH	●

Member of the Swiss Biotech Association ●

Company	Country	
Swati Spentose Pvt. Ltd.	IN	
SwedenBIO	SE	
Swiss Biotech Association	CH	
Swiss Biotech Center SA	CH	●
Swiss Business Hub India	IN	
Swiss Business Hub JP / Embassy of Switzerland in JP	JP	
Swiss Business Hub Korea	KR	
swiss finance leaders gmbh	CH	
Swiss Rockets AG	CH	
Swisslinx AG	CH	
Swissmedic, Swiss Agency for Therapeutic Products	CH	
Swissnex in Boston and New York	US	
Swissnex in JP	JP	
Switzerland Global Enterprise	CH	●
Swizzard Pharma AG	CH	●
SYDRA	CH	
Sygnature Discovery Limited	GB	
Symbiosis Pharmaceuticals	GB	
Symeres B.V.	NL	
SynCrest Inc.	JP	
Synendos Therapeutics AG	CH	●
Syneos Health	GB	
Syneos Health Switzerland GmbH	CH	●
Synexa Life Sciences	NL	
Syngene International Ltd	IN	
SYNVIA PARTICIPAÇÕES SOCIETÁRIAS LTDA	BR	
SYSTAG, System Technik AG	CH	
SyVento Sp. z o.o.	PL	
T-CURX GmbH	DE	
Taconic Biosciences GmbH	DE	
Taiwan Bio Industry Organization	TW	
Talentmark Ltd	GB	
Talisto GmbH	CH	●
Tamedia Finanz und Wirtschaft	CH	
Tandem Therapeutics AG	CH	●
Targimmune Therapeutics	CH	●
TDA UMZH Universität Zürich	CH	
Tebubio GmbH	DE	
Techniconsult Firenze Srl Società Benefit	IT	
ten23 health AG	CH	●
Tenpoint Therapeutics GmbH	CH	●
Terumo Corporation	JP	
Terumo Europe NV	BE	
Texcell	FR	
TFS Health Science / Appletree CI Group AG	CH	

Member of the Swiss Biotech Association ●

Company	Country	
The Art of Discovery S.L.	ES	
The RSA Group	CH	●
THEMIS S.p.A.	IT	
Theradex (Europe) Ltd	GB	
TheraMe! AG	CH	
Thermo Fisher Scientific Biologics Lengnau	CH	●
Thermo Fisher Scientific Life Technologies	CH	●
Thomas Schicker Konzeption und Gestaltung	CH	
Tigen Pharma SA	CH	●
Tigermed Swiss AG	CH	●
TissueLabs Sagl	CH	●
TVentures SA	CH	
Tokyo Oprea City Tower 49F, Nishi-Shinjuku, 3-20-2	JP	
TOLREMO therapeutics AG	CH	●
Toolpoint for Lab Science	CH	●
Topadur Pharma AG	CH	●
Topsector Life Sciences & Health Health~Holland	NL	
Total Solution Provider T-S-P GmbH	CH	
Translation-X	CH	
Trialyze AG	CH	●
Trials24 GmbH	DE	
Tridek-One Therapeutics SAS	CH	●
Trillione GmbH	CH	●
TROCKLE Unternehmensberatung	CH	
Tuari Therapeutics	DE	
Twist Bioscience Corporation	US	
UAB Biomatter Designs	LT	
UAB LEX ANO	LT	
UBS	GB	
UBS Switzerland AG	CH	
UK Essen	DE	
Umlaut.bio GmbH	CH	
Union for International Cancer Control (UICC)	CH	
Unither Pharmaceuticals	FR	
Università della Svizzera italiana (USI)	CH	
Università Vita-Salute San Raffaele	IT	
Universität Bern	CH	
University Hospital Bern	CH	
University Medical Center Freiburg	DE	
University Medical Center Utrecht	NL	
University of Applied Sciences and Arts Northwestern Switzerland	CH	
University of Basel	CH	
University of Geneva - Unitec	CH	
University of Helsinki	FI	
University of Zurich	CH	

Member of the Swiss Biotech Association ●

Company	Country	
Unlearn.ai	US	
Vaccentis AG	CH	●
Vaccine Formulation Institute (Institut de formulation des vaccins (CH) SA)	CH	●
Vaderis Therapeutics AG	CH	●
Validia	CH	
valuationLAB AG	CH	●
Vanderbilt University	US	
Vandria SA	CH	●
VantAI	US	
VCR Park Pvt. Ltd.	IN	
Vector BioPharma AG	CH	●
Veeda Clinical Research Limited	IN	
VelaLabs GmbH	AT	
Velvio GmbH Prof. Dr. Ulrich Bogdahn	DE	
Venn Life Sciences	NL	
Venture Foundation	CH	
Venture Valuation W AG	CH	●
Venturelab	CH	
Veranova	GB	
Versameb AG	CH	●
VERSANT VENTURES	CH	
Vesalius Biocapital III	LU	
Vetter Pharma International GmbH	DE	
Viatris	CH	
Viedoc Technologies AB	SE	
Viking Turizm Ve Ticaret A.s	TR	
VILS Switzerland GmbH	CH	●
Viopas Venture Consulting GmbH	CH	●
VirdisGroup Sàrl	CH	●
Virtuarch AG	CH	
VISCHER AG	CH	●
VitroScan	NL	
VivoArchitect	CH	
VJO Canada Inc	CA	
Voisin Consulting Life Sciences	CH	●
Vossius & Partner	CH	
VOXCAN	FR	
VSPHarmTech	KR	
Walder Wyss AG	CH	●
wega IT	CH	
Well Science AG	CH	
Wemedoo AG	CH	●
WEP Clinical	GB	
Westcore Sàrl	CH	
White Raven SA	BE	

Member of the Swiss Biotech Association ●

Company	Country	
Wiebecke Consulting AG	CH	
Willers Engineering AG	CH	
Winterthurerstrasse 190	CH	
Wirz & Partners	CH	
Witthoff Jaekel Steinecke Patentanwälte PartG mbB	DE	
World Courier SA	ES	
Worldwide Clinical Trials	GB / ES	
WuXi AppTec	CN / UK / CH	●
WuXi Biologics	CN / CH / DE / NL	
WuXi XDC Hong Kong Limited	CN / HK	
Wyss Zurich Translational Center	CH	●
X-Chem, Inc.	US	
X-HEALTH	CH	
Xcenda Switzerland GmbH	CH	●
XCubeBio AG	CH	●
Xinhua News Agency	CH	
Xlife Sciences AG	CH	●
YAFO Life Sciences Limited	CN	
Ymmunobio AG	CH	●
Yokogawa Innovation Switzerland GmbH	CH	●
Ysios Capital Partner SGEIC SA	ES	
Yuhan Corporation	KR	
YUMAB GmbH	DE	
ZACH SYSTEM	FR	
Zai Lab	US	
ZETA CH AG	CH	
ZHAW	CH	
ZoBio B.V.	NL	
Zühlke Engineering AG	CH	
Zurich University of Applied Sciences	CH	



# A big thank you to our sponsors

## Main sponsors



## Sponsors



## Supporting partners



## Host



Marketing: BIOCOM Interrelations GmbH | Event Organization: bamconn GmbH

... see you next year, May 5-6, 2025.

